

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
23 September 2004 (23.09.2004)

PCT

(10) International Publication Number  
**WO 2004/080398 A2**

(51) International Patent Classification<sup>7</sup>: **A61K** TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US2004/006867 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 5 March 2004 (05.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/453,128 7 March 2003 (07.03.2003) US  
60/532,191 23 December 2003 (23.12.2003) US

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW. ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(ii)) for all designations

(71) Applicant (for all designated States except US): **3M INNOVATIVE PROPERTIES COMPANY** [US/US]; 3M Center, Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GRIESGRABER, George W.**, [US/US]; Post Office Box 33327, Saint Paul, Minnesota 55133-3427 (US). **MANSKE, Karl J.**, [US/US]; Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US).

(74) Agents: **ERSFELD, Dean A.**, et al.; Office of Intellectual Property Counsel, Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

**Published:**

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/080398 A2

(54) Title: 1-AMINO 1H-IMIDAZOQUINOLINES

(57) Abstract: 1-Amino 1H-imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

1-AMINO 1*H*-IMIDAZOQUINOLINES

## FIELD OF THE INVENTION

5           This invention relates to 1-amino 1*H*-imidazoquinoline compounds, pharmaceutical compositions containing such compounds, intermediates used in their preparation, and the use of these compounds as immunomodulators.


## BACKGROUND OF THE INVENTION

10           There has been a major effort in recent years to find compounds that modulate the immune system. Examples of such compounds, which have demonstrated cytokine inducing and immunomodulating activity, are disclosed by U.S. Patent Nos. 4,689,338; 4,929,624; 5,266,575; 5,268,376; 5,352,784; 5,389,640; 5,446,153; 5,482,936; 5,494,916; 5,756,747; 6,110,929; 6,194,425; 6,331,539; 6,376,669; 6,451,810; 6,525,064; 6,541,485; 15   6,545,016; 6,545,017; 6,656,938; 6,660,735; 6,660,747; 6,664,260; 6,664,264; 6,664,265; 6,667,312; 6,670,372; 6,677,347; 6,677,348; and 6,683,088.


          But despite important progress in the effort to find immunomodulating compounds, there is still a critical scientific and medical need for additional compounds that have an ability to modulate aspects of the immune response, by induction of cytokine biosynthesis 20   or other mechanisms.

## SUMMARY OF THE INVENTION

          It has now been found that certain 1-amino 1*H*-imidazoquinoline compounds 25   modulate cytokine biosynthesis. In one aspect, the present invention provides compounds of the Formulas I and II:




I




II


5 and more specifically the following compounds of the Formulas I-1, I-2, I-3, and II-1:



I-1




I-2



I-3

10



II-1

wherein  $R_1'$ ,  $R_1$ ,  $R_2$ ,  $R_{2A}$ ,  $R_3$ ,  $R''$ ,  $R'''$ ,  $R$ ,  $R_A$ ,  $R_B$ ,  $n$  and  $m$  are as defined below; and pharmaceutically acceptable salts thereof.

5           The compounds of Formulas I, I-1, I-2, I-3, II, and II-1 are useful as immune response modifiers (IRMs) due to their ability to modulate cytokine biosynthesis (e.g., induce or inhibit the biosynthesis or production of one or more cytokines) and otherwise modulate the immune response when administered to animals. Compounds can be tested per the test procedures described in the Examples Section. Compounds can be tested for  
10 induction of cytokine biosynthesis by incubating human PBMC in a culture with the compound(s) at a concentration range of 30 to 0.014  $\mu\text{M}$  and analyzing for interferon ( $\alpha$ ) or tumor necrosis factor ( $\alpha$ ) in the culture supernatant. Compounds can be tested for inhibition of cytokine biosynthesis by incubating mouse macrophage cell line Raw 264.7 in a culture with the compound(s) at a single concentration of, for example, 5  $\mu\text{M}$  and  
15 analyzing for tumor necrosis factor ( $\alpha$ ) in the culture supernatant. The ability to modulate cytokine biosynthesis, for example, induce the biosynthesis of one or more cytokines, makes the compounds useful in the treatment of a variety of conditions such as viral diseases and neoplastic diseases, that are responsive to such changes in the immune response.

20           In another aspect, the present invention provides pharmaceutical compositions containing the immune response modifier compounds, and methods of inducing cytokine biosynthesis in animal cells, treating a viral disease in an animal, and/or treating a neoplastic disease in an animal by administering to the animal one or more compounds of the Formulas I, I-1, I-2, I-3, II, and/or II-1, and/or pharmaceutically acceptable salts  
25 thereof.

In another aspect, the invention provides methods of synthesizing the compounds of Formulas I, I-1, I-2, I-3, II, and II-1 and intermediates useful in the synthesis of these compounds.


As used herein, "a," "an," "the," "at least one," and "one or more" are used interchangeably.

The terms "comprising" and variations thereof do not have a limiting meaning where these terms appear in the description and claims.

5 The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. Guidance is also provided herein through lists of examples, which can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be  
10 interpreted as an exclusive list.

#### DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS OF THE INVENTION

In one aspect, the present invention provides 1-amino 1*H*-imidazoquinoline  
15 compounds of the following Formula I:



I

wherein:

$R_1'$  is selected from the group consisting of hydrogen and alkyl;

20  $R_1$  is selected from the group consisting of:

- $R_4$ ,

- $Y-R_4$ ,


- $X-R_5$ ,

- $X-N(R_6)-Y-R_4$ ,

25 - $X-C(R_7)-N(R_6)-R_4$ , and


- $X-O-R_4$ ;

or  $R_1'$  and  $R_1$  together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



$R_4$  is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when  $R_4$  is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which  $R_1$  is bonded;

$R_5$  is selected from the group consisting of:



each  $R_6$  is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;


$R_7$  is selected from the group consisting of =O and =S;

$R_8$  is C<sub>2-7</sub> alkylene;

$A$  is selected from the group consisting of -CH( $R_6$ )-, -O-, -N( $R_6$ )-, -N(Y- $R_4$ )-, and -N(X-N( $R_6$ )-Y- $R_4$ )-;

X is C<sub>2-20</sub> alkylene;

$Y$  is selected from the group consisting of -C( $R_7$ )-, -C( $R_7$ )-O-, -S(O)<sub>2</sub>-, -S(O)<sub>2</sub>-N( $R_6$ )-, and -C( $R_7$ )-N( $R_9$ )-; wherein  $R_9$  is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or  $R_9$  and  $R_4$  together with the nitrogen atom to which  $R_9$  is bonded can join to form the group



a and b are independently integers from 1 to 4 with the proviso that when A is -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, or -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)- then a and b are independently integers from 2 to 4;

each R'' is independently hydrogen or a non-interfering substituent;

5 each R''' is independently a non-interfering substituent; and

n is an integer from 0 to 4;

or a pharmaceutically acceptable salt thereof.

In some embodiments of Formula I, R'' is selected from the group consisting of:

- hydrogen,
- 10 -alkyl,
- alkenyl,
- aryl,
- heteroaryl,
- heterocyclyl,
- 15 -alkylene-Z-alkyl,
- alkylene-Z-aryl,
- alkylene-Z-alkenyl, and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
- 20 -OH,
- halogen,
- N(R<sub>6</sub>)<sub>2</sub>,
- C(R<sub>7</sub>)-N(R<sub>6</sub>)<sub>2</sub>,
- S(O)<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,
- 25 -N(R<sub>6</sub>)-C(R<sub>7</sub>)-C<sub>1-10</sub> alkyl,
- N(R<sub>6</sub>)-S(O)<sub>2</sub>-C<sub>1-10</sub> alkyl,
- C(O)-C<sub>1-10</sub> alkyl,
- C(O)-O-C<sub>1-10</sub> alkyl,
- N<sub>3</sub>,
- 30 -aryl,
- heteroaryl,
- heterocyclyl,

-C(O)-aryl, and  
-C(O)-heteroaryl;

each R<sub>6</sub> is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

5 each R<sub>7</sub> is independently selected from the group consisting of =O and =S; and Z is selected from the group consisting of -O- and -S(O)<sub>0-2</sub>-.

In some embodiments of Formula I, R<sup>n</sup> is R or R<sub>3</sub> when n is 1, R or one R and one R<sub>3</sub> when n is 2, or R when n is 3 to 4; wherein:

R is selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, 10 fluoroalkyl, hydroxy, amino, alkylamino, and dialkylamino;

R<sub>3</sub> is selected from the group consisting of:

-Z'-R<sub>4</sub>',  
-Z'-X'-R<sub>4</sub>',  
-Z'-X'-Y'-R<sub>4</sub>', and  
15 -Z'-X'-R<sub>5</sub>';


Z' is a bond or -O-;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene, 20 or heterocyclylene and optionally interrupted by one or more -O- groups;

Y' is selected from the group consisting of:

-S(O)<sub>0-2</sub>-,  
-S(O)<sub>2</sub>-N(R<sub>11</sub>)-,  
-C(R<sub>7</sub>)-,  
25 -C(R<sub>7</sub>)-O-,  
-O-C(R<sub>7</sub>)-,  
-O-C(O)-O-,  
-N(R<sub>11</sub>)-Q-,  
-C(R<sub>7</sub>)-N(R<sub>11</sub>)-,  
30 -O-C(R<sub>7</sub>)-N(R<sub>11</sub>)-,  
-C(R<sub>7</sub>)-N(OR<sub>12</sub>)-,






5

R<sub>4</sub>' is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

10

15

R<sub>5</sub>' is selected from the group consisting of:



each R<sub>7</sub> is independently selected from the group consisting of =O and =S;

each R<sub>8</sub> is independently C<sub>2-7</sub> alkylene;

R<sub>10</sub> is C<sub>3-8</sub> alkylene;

each R<sub>11</sub> is independently selected from the group consisting of hydrogen,

20

C<sub>1-10</sub> alkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkoxyC<sub>2-10</sub> alkylenyl, and arylC<sub>1-10</sub> alkylenyl;

R<sub>12</sub> is selected from the group consisting of hydrogen and alkyl;

A' is selected from the group consisting of -CH<sub>2</sub>-, -O-, -C(O)-, -S(O)<sub>0-2</sub>-, and -N(R<sub>4</sub>')-;


5 Q is selected from the group consisting of a bond, -C(R<sub>7</sub>)-, -C(R<sub>7</sub>)-C(R<sub>7</sub>)-, -S(O)<sub>2</sub>-, -C(R<sub>7</sub>)-N(R<sub>11</sub>)-W-, -S(O)<sub>2</sub>-N(R<sub>11</sub>)-, -C(R<sub>7</sub>)-O-, and -C(R<sub>7</sub>)-N(OR<sub>12</sub>)-;

V is selected from the group consisting of -C(R<sub>7</sub>)-, -O-C(R<sub>7</sub>)-, -N(R<sub>11</sub>)-C(R<sub>7</sub>)-, and -S(O)<sub>2</sub>-;

W is selected from the group consisting of a bond, -C(O)-, and -S(O)<sub>2</sub>-; and

10 c and d are independently integers from 1 to 6 with the proviso that c + d is ≤ 7, and when A' is -O- or -N(R<sub>4</sub>')- then c and d are independently integers from 2 to 4.

The present invention also provides 1-amino 6,7,8,9-tetrahydro 1*H*-imidazoquinoline compounds of the following Formula II:



II

15

wherein:

each R<sub>A</sub> is independently selected from the group consisting of:

halogen,

hydroxy,

20 alkyl,

alkenyl,

haloalkyl,

alkoxy,

alkylthio,

25 -NH<sub>2</sub>,

-NH(alkyl), and

-N(alkyl)<sub>2</sub>;

n is an integer from 0 to 4;


R<sub>1</sub>' is selected from the group consisting of hydrogen and alkyl;

R<sub>1</sub> is selected from the group consisting of:

- R<sub>4</sub>,
- Y-R<sub>4</sub>,
- X-R<sub>5</sub>,
- X-N(R<sub>6</sub>)-Y-R<sub>4</sub>,
- X-C(R<sub>7</sub>)-N(R<sub>6</sub>)-R<sub>4</sub>, and
- X-O-R<sub>4</sub>;

5

or R<sub>1</sub>' and R<sub>1</sub> together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:




10

R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R<sub>4</sub> is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R<sub>1</sub> is bonded;

20

R<sub>5</sub> is selected from the group consisting of:



25

each R<sub>6</sub> is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

R<sub>7</sub> is selected from the group consisting of =O and =S;


R<sub>8</sub> is C<sub>2-7</sub> alkylene;

A is selected from the group consisting of -CH(R<sub>6</sub>)-, -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, and

-N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)-;

X is C<sub>2-20</sub> alkylene;

Y is selected from the group consisting of -C(R<sub>7</sub>)-, -C(R<sub>7</sub>)-O-, -S(O)<sub>2</sub>-,  
 5 -S(O)<sub>2</sub>-N(R<sub>6</sub>)-, and -C(R<sub>7</sub>)-N(R<sub>9</sub>)-; wherein R<sub>9</sub> is selected from the group consisting of  
 hydrogen, alkyl, and arylalkylenyl; or R<sub>9</sub> and R<sub>4</sub> together with the nitrogen atom to which  
 R<sub>9</sub> is bonded can join to form the group




a and b are independently integers from 1 to 4 with the proviso that when A is  
 -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, or -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)- then a and b are independently integers  
 10 from 2 to 4; and

R'' is hydrogen or a non-interfering substituent;

or a pharmaceutically acceptable salt thereof.

The present invention also provides compounds of the following Formula I-1:



I-1

15


wherein:

R<sub>1</sub>' is selected from the group consisting of hydrogen and alkyl;

R<sub>1</sub> is selected from the group consisting of:

20 -R<sub>4</sub>,  
 -Y-R<sub>4</sub>,  
 -X-R<sub>5</sub>,  
 -X-N(R<sub>6</sub>)-Y-R<sub>4</sub>,  
 -X-C(R<sub>7</sub>)-N(R<sub>6</sub>)-R<sub>4</sub>, and  
 -X-O-R<sub>4</sub>;

25 or R<sub>1</sub>' and R<sub>1</sub> together with the nitrogen atom to which they are bonded can join to  
 form a group selected from the group consisting of:




R<sub>2</sub> is selected from the group consisting of:

- hydrogen,
- alkyl,
- 5 -alkenyl,
- aryl,
- heteroaryl,
- heterocyclyl,
- alkylene-Z-alkyl,
- 10 -alkylene-Z-aryl,
- alkylene-Z-alkenyl, and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

- OH,
- 15 -halogen,
- N(R<sub>6</sub>)<sub>2</sub>,
- C(R<sub>7</sub>)-N(R<sub>6</sub>)<sub>2</sub>,
- S(O)<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,
- N(R<sub>6</sub>)-C(R<sub>7</sub>)-C<sub>1-10</sub> alkyl,
- 20 -N(R<sub>6</sub>)-S(O)<sub>2</sub>-C<sub>1-10</sub> alkyl,
- C(O)-C<sub>1-10</sub> alkyl,
- C(O)-O-C<sub>1-10</sub> alkyl,
- N<sub>3</sub>,
- aryl,
- 25 -heteroaryl,
- heterocyclyl,
- C(O)-aryl, and
- C(O)-heteroaryl;

R<sub>3</sub> is selected from the group consisting of:

- 30 -Z'-R<sub>4</sub>'




each R is independently selected from the group consisting of alkyl, alkenyl,  
 5 alkoxy, halogen, fluoroalkyl, hydroxy, amino, alkylamino, and dialkylamino;

n is an integer from 0 to 4;  
 m is 0 or 1; with the proviso that when m is 1, then n is 0 or 1;


R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl,  
 heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and  
 10 heterocyclyl groups can be unsubstituted or substituted by one or more substituents  
 independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy,  
 halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy,  
 heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino,  
 alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl,  
 15 and heterocyclyl, oxo, with the proviso that when R<sub>4</sub> is a substituted alkyl group and the  
 substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl  
 group contains at least two carbons between the substituent and the nitrogen atom to  
 which R<sub>1</sub> is bonded;

R<sub>5</sub> is selected from the group consisting of:



X is C<sub>2-20</sub> alkylene;

Y is selected from the group consisting of -C(R<sub>7</sub>)-, -C(R<sub>7</sub>)-O-, -S(O)<sub>2</sub>-,  
 -S(O)<sub>2</sub>-N(R<sub>6</sub>)-, and -C(R<sub>7</sub>)-N(R<sub>9</sub>)-; wherein R<sub>9</sub> is selected from the group consisting of  
 hydrogen, alkyl, and arylalkylenyl; or R<sub>9</sub> and R<sub>4</sub> together with the nitrogen atom to which  
 25 R<sub>9</sub> is bonded can join to form the group



Z is selected from the group consisting of -O- and -S(O)<sub>0-2</sub>;


A is selected from the group consisting of -CH(R<sub>6</sub>)-, -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, and

-N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)-;

a and b are independently integers from 1 to 4 with the proviso that when A is -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, or -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)- then a and b are independently integers from 2 to 4;

5           R<sub>4</sub>' is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups  
10 can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl,  
15 oxo;


R<sub>5</sub>' is selected from the group consisting of:



X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and  
20 alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene, or heterocyclylene and optionally interrupted by one or more -O- groups;

Y' is selected from the group consisting of:

25           -S(O)<sub>0-2</sub>-,  
             -S(O)<sub>2</sub>-N(R<sub>11</sub>)-,  
             -C(R<sub>7</sub>)-,  
             -C(R<sub>7</sub>)-O-,  
             -O-C(R<sub>7</sub>)-,  
             -O-C(O)-O-,  
             -N(R<sub>11</sub>)-Q-,  
30           -C(R<sub>7</sub>)-N(R<sub>11</sub>)-,



5

10

15

20

$Z'$  is a bond or  $-O-$ ;  
 $A'$  is selected from the group consisting of  $-CH_2-$ ,  $-O-$ ,  $-C(O)-$ ,  $-S(O)_{0-2}-$ , and  $-N(R_4)-$ ;  
 $Q$  is selected from the group consisting of a bond,  $-C(R_7)-$ ,  $-C(R_7)-C(R_7)-$ ,  $-S(O)_2-$ ,  $-C(R_7)-N(R_{11})-W-$ ,  $-S(O)_2-N(R_{11})-$ ,  $-C(R_7)-O-$ , and  $-C(R_7)-N(OR_{12})-$ ;  
 $V$  is selected from the group consisting of  $-C(R_7)-$ ,  $-O-C(R_7)-$ ,  $-N(R_{11})-C(R_7)-$ , and  $-S(O)_2-$ ;  
 $W$  is selected from the group consisting of a bond,  $-C(O)-$ , and  $-S(O)_2-$ ;  
 $c$  and  $d$  are independently integers from 1 to 6 with the proviso that  $c + d$  is  $\leq 7$ ,  
 and when  $A'$  is  $-O-$  or  $-N(R_4)-$  then  $c$  and  $d$  are independently integers from 2 to 4;  
 each  $R_6$  is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;  
 each  $R_7$  is independently selected from the group consisting of  $=O$  and  $=S$ ;  
 each  $R_8$  is independently  $C_{2-7}$  alkylene;  
 $R_{10}$  is  $C_{3-8}$  alkylene;  
 each  $R_{11}$  is independently selected from the group consisting of hydrogen,  $C_{1-10}$  alkyl,  $C_{2-10}$  alkenyl,  $C_{1-10}$  alkoxy $C_{2-10}$  alkylenyl, and aryl $C_{1-10}$  alkylenyl; and



$R_{12}$  is selected from the group consisting of hydrogen and alkyl;  
or a pharmaceutically acceptable salt thereof.

In some embodiments of Formula I-1,  $R_1$  is selected from the group consisting of  
- $R_4$ , - $Y-R_4$ , and - $X-N(R_6)-Y-R_4$  wherein  $Y$  is - $C(R_7)-$ , - $S(O)_2-$ , or - $C(R_7)-N(R_9)-$ .


5 In certain embodiments of Formula I-1,  $R_1$  is selected from the group consisting of  
hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl,  
heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl,  
alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl,  
arylaminoacarbonyl, (arylalkylenyl)aminoalkylenyl, and  
10 arylaminocarbonylaminoalkylenyl.

In certain embodiments of Formula I-1,  $R_1$  is selected from the group consisting of  
hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl,  
cyclohexyl, benzyl, 3-phenylpropyl, cinnamyl, furan-2-ylmethyl, and  
- $CH_2CH_2CH_2-NHR_{13}$ , wherein  $R_{13}$  is selected from the group consisting of  
15 methanesulfonyl, phenylsulfonyl, benzyl, isopropylaminocarbonyl, and  
phenylaminocarbonyl.

In some embodiments of Formula I-1,  $R_1'$  is hydrogen.

In some embodiments of Formula I-1,  $R_1$  and  $R_1'$  are each independently alkyl.

In some embodiments of Formula I-1,  $R_1$  and  $R_1'$  join to form the group:




20

In some embodiments of Formula I-1,  $R_2$  is selected from the group consisting of  
hydrogen, alkyl, and alkoxyalkylenyl, and in certain embodiments  $R_2$  is selected from the  
group consisting of hydrogen, methyl, propyl, butyl, 2-methoxyethyl, and ethoxymethyl.

In some embodiments of Formula I-1,  $n$  is 0.

25 In some embodiments of Formula I-1,  $n$  is 0, and  $R_3$  is selected from the group  
consisting of - $Z'-R_4'$ , - $Z'-X'-R_4'$ , and - $Z'-X'-Y'-R_4'$ , and in certain embodiments  $R_3$  is  
selected from the group consisting of 2-(pyridin-3-yl)ethyl, pyridinyl,  
hydroxymethylpyridinyl, ethoxyphenyl, (morpholine-4-carbonyl)phenyl,  
2-(methanesulfonylamino)ethoxy, and benzyloxy.

30 The present invention also provides compounds of the following Formula (I-2):



I-2

wherein:

$R_B$  is selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;


$n$  is an integer from 0 to 4;

$R_1'$  is selected from the group consisting of hydrogen and alkyl;

$R_1$  is selected from the group consisting of:

- $R_4$ ,
- $Y-R_4$ ,
- $X-R_5$ ,
- $X-N(R_6)-Y-R_4$ ,
- $X-C(R_7)-N(R_6)-R_4$ , and
- $X-O-R_4$ ;

or  $R_1'$  and  $R_1$  together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



$R_2$  is selected from the group consisting of:


- hydrogen,
- alkyl,
- alkenyl,
- aryl,
- heteroaryl,
- heterocyclyl,
- alkylene-Z-alkyl,
- alkylene-Z-aryl,

-alkylene-Z-alkenyl, and  
 -alkyl or alkenyl substituted by one or more substituents selected from the  
 group consisting of:

- 5                   -OH,  
                   -halogen,  
                   -N(R<sub>6</sub>)<sub>2</sub>,  
                   -C(R<sub>7</sub>)-N(R<sub>6</sub>)<sub>2</sub>,  
                   -S(O)<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,  
 10                  -N(R<sub>6</sub>)-C(R<sub>7</sub>)-C<sub>1-10</sub> alkyl,  
                   -N(R<sub>6</sub>)-S(O)<sub>2</sub>-C<sub>1-10</sub> alkyl,  
                   -C(O)-C<sub>1-10</sub> alkyl,  
                   -C(O)-O-C<sub>1-10</sub> alkyl,  
                   -N<sub>3</sub>,  
                   -aryl,  
 15                  -heteroaryl,  
                   -heterocyclyl,  
                   -C(O)-aryl, and  
                   -C(O)-heteroaryl;

20                  R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl,  
 heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and  
 heterocyclyl groups can be unsubstituted or substituted by one or more substituents  
 independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy,  
 halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy,  
 heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino,  
 25                  alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl,  
 and heterocyclyl, oxo, with the proviso that when R<sub>4</sub> is a substituted alkyl group and the  
 substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl  
 group contains at least two carbons between the substituent and the nitrogen atom to  
 which R<sub>1</sub> is bonded;

30                  R<sub>5</sub> is selected from the group consisting of:



each  $R_6$  is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;


each  $R_7$  is independently selected from the group consisting of =O and =S;

5  $R_8$  is  $C_{2-7}$  alkylene;

A is selected from the group consisting of  $-\text{CH}(R_6)-$ ,  $-\text{O}-$ ,  $-\text{N}(R_6)-$ ,  $-\text{N}(Y-R_4)-$ , and  $-\text{N}(X-\text{N}(R_6)-Y-R_4)-$ ;

X is  $C_{2-20}$  alkylene;

10 Y is selected from the group consisting of  $-\text{C}(R_7)-$ ,  $-\text{C}(R_7)-\text{O}-$ ,  $-\text{S}(\text{O})_2-$ ,  $-\text{S}(\text{O})_2-\text{N}(R_6)-$ , and  $-\text{C}(R_7)-\text{N}(R_9)-$ ; wherein  $R_9$  is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or  $R_9$  and  $R_4$  together with the nitrogen atom to which  $R_9$  is bonded can join to form the group



Z is selected from the group consisting of  $-\text{O}-$  and  $-\text{S}(\text{O})_{0-2}-$ ; and

15 a and b are independently integers from 1 to 4 with the proviso that when A is  $-\text{O}-$ ,  $-\text{N}(R_6)-$ ,  $-\text{N}(Y-R_4)-$ , or  $-\text{N}(X-\text{N}(R_6)-Y-R_4)-$  then a and b are independently integers from 2 to 4;

or a pharmaceutically acceptable salt thereof.

20 In some embodiments of Formula I-2,  $R_1$  is selected from the group consisting of  $-\text{R}_4$ ,  $-\text{Y}-\text{R}_4$ , and  $-\text{X}-\text{N}(R_6)-\text{Y}-\text{R}_4$  wherein Y is  $-\text{C}(R_7)-$ ,  $-\text{S}(\text{O})_2-$ , or  $-\text{C}(R_7)-\text{N}(R_9)-$ .

In certain embodiments of Formula I-2,  $R_1$  is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, and arylaminocarbonylaminoalkylenyl.


In certain embodiments of Formula I-2,  $R_1$  is selected from the group consisting of hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl,

cyclohexyl, benzyl, cinnamyl, furan-2-ylmethyl, and  $-\text{CH}_2\text{CH}_2\text{CH}_2-\text{NHR}_{13}$ , wherein  $\text{R}_{13}$  is selected from the group consisting of methanesulfonyl, phenylsulfonyl, benzyl, and phenylaminocarbonyl.

In some embodiments of Formula I-2,  $\text{R}_1'$  is hydrogen.

5 In some embodiments of Formula I-2,  $\text{R}_1$  and  $\text{R}_1'$  are each independently alkyl.

In some embodiments of Formula I-2,  $\text{R}_1$  and  $\text{R}_1'$  join to form the group:




10 In some embodiments of Formula I-2,  $\text{R}_2$  is selected from the group consisting of hydrogen, alkyl, and alkoxyalkylenyl, and in certain embodiments  $\text{R}_2$  is selected from the group consisting of hydrogen, butyl, 2-methoxyethyl, and ethoxymethyl.

In some embodiments of Formula I-2,  $n$  is 0.

In some embodiments of Formula I-2,  $n$  is 1, and  $\text{R}$  is halogen or hydroxy.

The present invention also provides compounds of the following Formula (I-3):



I-3

15

wherein:

$\text{R}_B$  is selected from alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;

$n$  is an integer from 0 to 4;

$\text{R}_1'$  is selected from hydrogen and alkyl;

20

$\text{R}_1$  is selected from:

$-\text{R}_4$ ,

$-\text{Y}-\text{R}_4$ ,

$-\text{X}-\text{R}_5$ ,


$-\text{X}-\text{N}(\text{R}_6)-\text{Y}-\text{R}_4$ ,

25

$-\text{X}-\text{CR}_7-\text{N}(\text{R}_6)-\text{R}_4$ , and

$-\text{X}-\text{O}-\text{R}_4$ ;

or R<sub>1</sub>' and R<sub>1</sub> together with the nitrogen atom to which they are bonded can join to form a group selected from:




R<sub>2A</sub> is selected from:

- 5            -hydrogen,
- alkyl,
- alkenyl,
- aryl,
- heteroaryl,
- 10          -alkylene-Z-alkyl,
- alkylene-Z-aryl,
- alkylene-Z- alkenyl, and
- alkyl or alkenyl substituted by one or more substituents selected from:
- OH,
- 15          -halogen,
- N(R<sub>6</sub>)<sub>2</sub>,
- CR<sub>7</sub>-N(R<sub>6</sub>)<sub>2</sub>,
- SO<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,
- N(R<sub>6</sub>)-CR<sub>7</sub>-C<sub>1-10</sub> alkyl,
- 20          -N(R<sub>6</sub>)- SO<sub>2</sub>-C<sub>1-10</sub> alkyl,
- C(O)-C<sub>1-10</sub> alkyl,
- C(O)-O-C<sub>1-10</sub> alkyl,
- N<sub>3</sub>,
- aryl,
- 25          -heteroaryl,
- heterocyclyl,
- C(O)-aryl, and
- C(O)-heteroaryl;

R<sub>4</sub> is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and  
 30 heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups

can be unsubstituted or substituted by one or more substituents independently selected from alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R<sub>4</sub> is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R<sub>1</sub> is bonded;

R<sub>5</sub> is selected from:




R<sub>6</sub> is selected from hydrogen, alkyl, and arylalkylenyl;

R<sub>7</sub> is selected from =O and =S;

R<sub>8</sub> is C<sub>2-7</sub> alkylene;

15 R<sub>9</sub> is selected from hydrogen, alkyl, and arylalkylenyl, or R<sub>9</sub> and R<sub>4</sub> together with the nitrogen atom to which R<sub>9</sub> is bonded can join to form the group



A is selected from -CHR<sub>6</sub>-, -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, and -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)-;

X is C<sub>2-20</sub> alkylene;

Y is selected from -CR<sub>7</sub>-, -SO<sub>2</sub>-, -SO<sub>2</sub>-N(R<sub>6</sub>)-, and -CR<sub>7</sub>-N(R<sub>9</sub>)-;

20 Z is selected from -O- and -S(O)<sub>0-2</sub>-;

a and b are independently integers from 1 to 4 with the proviso that when A is -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, or -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)- then a and b are independently integers from 2 to 4;

and pharmaceutically acceptable salts thereof.

25 In some embodiments of Formula I-3, R<sub>1</sub> is selected from -R<sub>4</sub>, -Y-R<sub>4</sub>, and -X-N(R<sub>6</sub>)-Y-R<sub>4</sub> wherein Y is -CR<sub>7</sub>-, -SO<sub>2</sub>-, or -CR<sub>7</sub>-N(R<sub>9</sub>)-.

In certain embodiments of Formula I-3, R<sub>1</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl,

heteroarylalkenyl, aminoalkyl, alkoxyalkyl, acyl,  
alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylaminocarbonyl,  
arylaminocarbonyl, (arylalkyl)aminoalkyl, and  
arylaminocarbonylaminoalkyl.


5 In certain embodiments of Formula I-3,  $R_1$  is selected from hydrogen, isopropyl, butyl, cyclohexyl, benzyl, cinnamyl, and  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{-NHR}_{13}$ , wherein  $R_{13}$  is selected from methanesulfonyl, phenylsulfonyl, benzyl, and phenylaminocarbonyl.

In some embodiments of Formula I-3,  $R_1'$  is hydrogen.

10 In some embodiments of Formula I-3,  $R_{2A}$  is selected from hydrogen, alkyl, and alkoxyalkyl, and in certain embodiments  $R_{2A}$  is selected from hydrogen, butyl, methoxyethyl (e.g., 2-methoxyethyl), and ethoxymethyl.

In some embodiments of Formula I-3,  $n$  is 0.

The present invention also provides compounds of the following Formula (II-1):



II-1

wherein:

each  $R_A$  is independently selected from the group consisting of:

20 halogen,  
hydroxy,  
alkyl,  
alkenyl,  
haloalkyl,  
25 alkoxy,  
alkylthio,  
- $\text{NH}_2$ ,  
- $\text{NH}(\text{alkyl})$ , and



-N(alkyl)<sub>2</sub>;

n is an integer from 0 to 4;

R<sub>1</sub>' is selected from the group consisting of hydrogen and alkyl;

R<sub>1</sub> is selected from the group consisting of:

5

-R<sub>4</sub>,

-Y-R<sub>4</sub>,

-X-R<sub>5</sub>,


-X-N(R<sub>6</sub>)-Y-R<sub>4</sub>,

-X-C(R<sub>7</sub>)-N(R<sub>6</sub>)-R<sub>4</sub>, and

10

-X-O-R<sub>4</sub>;

or R<sub>1</sub>' and R<sub>1</sub> together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



R<sub>2</sub> is selected from the group consisting of:

15

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

20

-heterocyclyl,

-alkylene-Z-alkyl,

-alkylene-Z-aryl,

-alkylene-Z-alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

25

-OH,

-halogen,

-N(R<sub>6</sub>)<sub>2</sub>,

-C(R<sub>7</sub>)-N(R<sub>6</sub>)<sub>2</sub>,


30

-S(O)<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,

- N(R<sub>6</sub>)-C(R<sub>7</sub>)-C<sub>1-10</sub> alkyl,
- N(R<sub>6</sub>)-S(O)<sub>2</sub>-C<sub>1-10</sub> alkyl,
- C(O)-C<sub>1-10</sub> alkyl,
- C(O)-O-C<sub>1-10</sub> alkyl,
- 5 -N<sub>3</sub>,
- aryl,
- heteroaryl,
- heterocyclyl,
- C(O)-aryl, and
- 10 -C(O)-heteroaryl;

R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R<sub>4</sub> is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R<sub>1</sub> is bonded;

R<sub>5</sub> is selected from the group consisting of:



each R<sub>6</sub> is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

each R<sub>7</sub> is independently selected from the group consisting of =O and =S;

R<sub>8</sub> is C<sub>2-7</sub> alkylene;


A is selected from the group consisting of -CH(R<sub>6</sub>)-, -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, and -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)-;

X is C<sub>2-20</sub> alkylene;



In some embodiments of Formula II-1,  $R_1$  and  $R_1'$  are each independently alkyl.

In some embodiments of Formula II-1,  $R_1$  and  $R_1'$  join to form the group:




In some embodiments of Formula II-1,  $R_2$  is selected from the group consisting of hydrogen, alkyl, and alkoxyalkylenyl, in certain embodiments  $R_2$  is selected from the group consisting of hydrogen, butyl, 2-methoxyethyl, and ethoxymethyl, and in certain embodiments  $R_2$  is selected from the group consisting of hydrogen, methyl, propyl, butyl, 2-methoxyethyl, and ethoxymethyl.

In some embodiments of Formula II-1,  $n$  is 0.

The present invention also provides compounds that are useful as intermediates in the synthesis of compounds of Formula I, I-1, I-2, I-3, II, and/or II-1. These intermediate compounds have the structural Formulas VII, IX, X, XLII, and XLIII described below.

The present invention provides intermediate compounds of the following Formula (VII):



VII

wherein:

each  $R_B$  is independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;

$n$  is an integer from 0 to 4;

$R_2$  is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-heterocyclyl,

-alkylene-Z-alkyl,  
-alkylene-Z-aryl,  
-alkylene-Z-alkenyl, and  
-alkyl or alkenyl substituted by one or more substituents selected from the  
5 group consisting of:


-OH,  
-halogen,  
-N(R<sub>6</sub>)<sub>2</sub>,  
-C(R<sub>7</sub>)-N(R<sub>6</sub>)<sub>2</sub>,  
10 -S(O)<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,  
-N(R<sub>6</sub>)-C(R<sub>7</sub>)-C<sub>1-10</sub> alkyl,  
-N(R<sub>6</sub>)-S(O)<sub>2</sub>-C<sub>1-10</sub> alkyl,  
-C(O)-C<sub>1-10</sub> alkyl,  
-C(O)-O-C<sub>1-10</sub> alkyl,  
15 -N<sub>3</sub>,  
-aryl,  
-heteroaryl,  
-heterocyclyl,  
-C(O)-aryl, and  
20 -C(O)-heteroaryl;

each R<sub>6</sub> is independently selected from the group consisting of hydrogen, alkyl,  
and arylalkylenyl;

R<sub>7</sub> is selected from the group consisting of =O and =S; and

Z is selected from the group consisting of -O- and -S(O)<sub>0-2</sub>;  
25 or a pharmaceutically acceptable salt thereof.

The present invention also provides intermediate compounds of the following Formula (IX):



IX

5 wherein:

each  $R_B$  is independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;

$n$  is an integer from 0 to 4;

$R_1'$  is hydrogen or alkyl;

10  $R_1$  is selected from the group consisting of:

- $R_4$ ,

- $Y-R_4$ ,


- $X-R_5$ ,

- $X-N(R_6)-Y-R_4$ ,

15 - $X-C(R_7)-N(R_6)-R_4$ , and

- $X-O-R_4$ ;

or  $R_1'$  and  $R_1$  together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



20  $R_2$  is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

25 -heteroaryl,

-heterocyclyl,


-alkylene-Z-alkyl,

-alkylene-Z-aryl,  
 -alkylene-Z-alkenyl, and  
 -alkyl or alkenyl substituted by one or more substituents selected from the  
 group consisting of:

- 5                   -OH,  
                   -halogen,  
                   -N(R<sub>6</sub>)<sub>2</sub>,  
                   -C(R<sub>7</sub>)-N(R<sub>6</sub>)<sub>2</sub>,  
                   -S(O)<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,  
 10               -N(R<sub>6</sub>)-C(R<sub>7</sub>)-C<sub>1-10</sub> alkyl,  
                   -N(R<sub>6</sub>)-S(O)<sub>2</sub>-C<sub>1-10</sub> alkyl,  
                   -C(O)-C<sub>1-10</sub> alkyl,  
                   -C(O)-O-C<sub>1-10</sub> alkyl,  
                   -N<sub>3</sub>,  
 15               -aryl,  
                   -heteroaryl,  
                   -heterocyclyl,  
                   -C(O)-aryl, and  
                   -C(O)-heteroaryl;

20               R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl,  
 heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and  
 heterocyclyl groups can be unsubstituted or substituted by one or more substituents  
 independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy,  
 halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy,  
 25               heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino,  
 alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl,  
 and heterocyclyl, oxo, with the proviso that when R<sub>4</sub> is a substituted alkyl group and the  
 substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl  
 group contains at least two carbons between the substituent and the nitrogen atom to  
 30               which R<sub>1</sub> is bonded;

R<sub>5</sub> is selected from the group consisting of



each R<sub>6</sub> is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;


each R<sub>7</sub> is independently selected from the group consisting of =O and =S;

5 R<sub>8</sub> is C<sub>2-7</sub> alkylene;

A is selected from the group consisting of -CH(R<sub>6</sub>)-, -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, and -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)-;

X is C<sub>2-20</sub> alkylene;

10 Y is selected from the group consisting of -C(R<sub>7</sub>)-, -C(R<sub>7</sub>)-O-, -S(O)<sub>2</sub>-, -S(O)<sub>2</sub>-N(R<sub>6</sub>)-, and -C(R<sub>7</sub>)-N(R<sub>9</sub>)-; wherein R<sub>9</sub> is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or R<sub>9</sub> and R<sub>4</sub> together with the nitrogen atom to which R<sub>9</sub> is bonded can join to form the group




Z is selected from the group consisting of -O- and -S(O)<sub>0-2</sub>-; and

15 a and b are independently integers from 1 to 4 with the proviso that when A is -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, or -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)- then a and b are independently integers from 2 to 4;

or a pharmaceutically acceptable salt thereof.

20 The present invention also provides intermediate compounds of the following Formula (X):



X

wherein:

25 each R<sub>B</sub> is independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;




n is an integer from 0 to 4;

R<sub>1</sub>' is hydrogen or alkyl;

R<sub>1a</sub> is selected from the group consisting of:

- R<sub>4a</sub>,
- 5 -Y-R<sub>4a</sub>,
- X-R<sub>5</sub>,
- X-N(R<sub>6</sub>)-Y-R<sub>4a</sub>,
- X-C(R<sub>7</sub>)-N(R<sub>6</sub>)-R<sub>4a</sub>, and
- X-O-R<sub>4a</sub>;

10 or R<sub>1</sub>' and R<sub>1a</sub> together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



R<sub>2a</sub> is selected from the group consisting of:

- hydrogen,
- 15 -alkyl,
- alkenyl,
- aryl,
- alkylene-Z"-alkyl,
- alkylene-Z"-aryl,
- 20 -alkylene-Z"- alkenyl, and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

- OH,
- halogen,
- 25 -N(R<sub>6</sub>)<sub>2</sub>,
- C(R<sub>7</sub>)-N(R<sub>6</sub>)<sub>2</sub>,
- S(O)<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,
- N(R<sub>6</sub>)-C(R<sub>7</sub>)-C<sub>1-10</sub> alkyl,
- N(R<sub>6</sub>)- S(O)<sub>2</sub>-C<sub>1-10</sub> alkyl,
- 30 -C(O)-C<sub>1-10</sub> alkyl,


- C(O)-O-C<sub>1-10</sub> alkyl,
- N<sub>3</sub>,
- aryl,
- heterocyclyl, and
- C(O)-aryl;

5

R<sub>4a</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, 10 alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R<sub>4a</sub> is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R<sub>1</sub> is bonded;

15

R<sub>5</sub> is selected from the group consisting of



each R<sub>6</sub> is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

20

each R<sub>7</sub> is independently selected from the group consisting of =O and =S;


R<sub>8</sub> is C<sub>2-7</sub> alkylene;

A is selected from the group consisting of -CH(R<sub>6</sub>)-, -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, and -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)-;

X is C<sub>2-20</sub> alkylene;

25

Y is selected from the group consisting of -C(R<sub>7</sub>)-, -C(R<sub>7</sub>)-O-, -S(O)<sub>2</sub>-, -S(O)<sub>2</sub>-N(R<sub>6</sub>)-, and -C(R<sub>7</sub>)-N(R<sub>9</sub>)-; wherein R<sub>9</sub> is selected from the group consisting of hydrogen, alkyl and arylalkylenyl, or R<sub>9</sub> and R<sub>4</sub> together with the nitrogen atom to which R<sub>9</sub> is bonded can join to form the group




Z" is selected from the group consisting of -O- and -S(O)<sub>2</sub>-; and

a and b are independently integers from 1 to 4 with the proviso that when A is -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, or -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)- then a and b are independently integers from 2 to 4;

or a pharmaceutically acceptable salt thereof.

The present invention also provides intermediate compounds of the following Formula (XLII):



XLII

wherein:

R is selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, fluoroalkyl, hydroxy, amino, alkylamino, and dialkylamino;

l is 0 or 1;

R<sub>2</sub> is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-heterocyclyl,

-alkylene-Z-alkyl,

-alkylene-Z-aryl,

-alkylene-Z-alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:


- OH,  
 -halogen,  
 -N(R<sub>6</sub>)<sub>2</sub>,  
 -C(R<sub>7</sub>)-N(R<sub>6</sub>)<sub>2</sub>,  
 5 -S(O)<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,  
 -N(R<sub>6</sub>)-C(R<sub>7</sub>)-C<sub>1-10</sub> alkyl,  
 -N(R<sub>6</sub>)-S(O)<sub>2</sub>-C<sub>1-10</sub> alkyl,  
 -C(O)-C<sub>1-10</sub> alkyl,  
 -C(O)-O-C<sub>1-10</sub> alkyl,  
 10 -N<sub>3</sub>,  
 -aryl,  
 -heteroaryl,  
 -heterocyclyl,  
 -C(O)-aryl, and  
 15 -C(O)-heteroaryl;

each R<sub>6</sub> is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

R<sub>7</sub> is selected from the group consisting of =O and =S; and

Z is selected from the group consisting of -O- and -S(O)<sub>0-2</sub>;  
 20 or a pharmaceutically acceptable salt thereof.

The present invention also provides intermediate compounds of the following Formula (XLIII):



25

XLIII

wherein:

R is selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, fluoroalkyl, hydroxy, amino, alkylamino, and dialkylamino;


l is 0 or 1;

R<sub>1</sub>' is hydrogen or alkyl;

R<sub>1</sub> is selected from the group consisting of:

- R<sub>4</sub>,
- 5 -Y-R<sub>4</sub>,
- X-R<sub>5</sub>,
- X-N(R<sub>6</sub>)-Y-R<sub>4</sub>,
- X-C(R<sub>7</sub>)-N(R<sub>6</sub>)-R<sub>4</sub>, and
- X-O-R<sub>4</sub>;

10 or R<sub>1</sub>' and R<sub>1</sub> together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:




R<sub>2</sub> is selected from the group consisting of:

- hydrogen,
- 15 -alkyl,
- alkenyl,
- aryl,
- heteroaryl,
- heterocyclyl,
- 20 -alkylene-Z-alkyl,
- alkylene-Z-aryl,
- alkylene-Z-alkenyl, and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
- 25 -OH,
- halogen,
- N(R<sub>6</sub>)<sub>2</sub>,
- C(R<sub>7</sub>)-N(R<sub>6</sub>)<sub>2</sub>,
- S(O)<sub>2</sub>-N(R<sub>6</sub>)<sub>2</sub>,
- 30 -N(R<sub>6</sub>)-C(R<sub>7</sub>)-C<sub>1-10</sub> alkyl,

- N(R<sub>6</sub>)-S(O)<sub>2</sub>-C<sub>1-10</sub> alkyl,
- C(O)-C<sub>1-10</sub> alkyl,
- C(O)-O-C<sub>1-10</sub> alkyl,
- N<sub>3</sub>,
- aryl,
- heteroaryl,
- heterocyclyl,
- C(O)-aryl, and
- C(O)-heteroaryl;

R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R<sub>4</sub> is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R<sub>1</sub> is bonded;

R<sub>5</sub> is selected from the group consisting of



each R<sub>6</sub> is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

each R<sub>7</sub> is independently selected from the group consisting of =O and =S;


R<sub>8</sub> is C<sub>2-7</sub> alkylene;

A is selected from the group consisting of -CH(R<sub>6</sub>)-, -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, and -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)-;

X is C<sub>2-20</sub> alkylene;

Y is selected from the group consisting of -C(R<sub>7</sub>)-, -C(R<sub>7</sub>)-O-, -S(O)<sub>2</sub>-,

-S(O)<sub>2</sub>-N(R<sub>6</sub>)-, and -C(R<sub>7</sub>)-N(R<sub>9</sub>)-; wherein R<sub>9</sub> is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or R<sub>9</sub> and R<sub>4</sub> together with the nitrogen atom to which R<sub>9</sub> is bonded can join to form the group



- 5            Z is selected from the group consisting of -O- and -S(O)<sub>0-2</sub>-; and  
               a and b are independently integers from 1 to 4 with the proviso that when A is  
               -O-, -N(R<sub>6</sub>)-, -N(Y-R<sub>4</sub>)-, or -N(X-N(R<sub>6</sub>)-Y-R<sub>4</sub>)- then a and b are independently integers  
               from 2 to 4;  
               or a pharmaceutically acceptable salt thereof.

10

              Herein, "non-interfering" means that the ability of the compound or salt to  
               modulate (e.g., induce or inhibit) the biosynthesis of one or more cytokines is not  
               destroyed by the non-interfering substituent. Illustrative non-interfering R" groups  
               include those described above for R<sub>2</sub> in Formulas I-1, I-2, and II-1, and for R<sub>2A</sub> in Formula  
 15            I-3. Illustrative non-interfering R'" groups include those described above for R and R<sub>3</sub> in  
               Formula I-1, and for R<sub>B</sub> in Formulas I-2 and I-3.

              As used herein, the terms "alkyl," "alkenyl," "alkynyl" and the prefix "alk-" are  
               inclusive of both straight chain and branched chain groups and of cyclic groups, i.e.  
               cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to  
 20            20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms, and alkynyl  
               groups containing from 2 to 20 carbon atoms. In some embodiments, these groups have a  
               total of up to 10 carbon atoms, up to 8 carbon atoms, up to 6 carbon atoms, or up to 4  
               carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3  
               to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl,  
 25            cyclopropylmethyl, cyclopentyl, cyclohexyl, adamantyl, and substituted and unsubstituted  
               bornyl, norbornyl, and norbornenyl.

              Unless otherwise specified, "alkylene," "alkenylene," and "alkynylene" are the  
               divalent forms of the "alkyl," "alkenyl," and "alkynyl" groups defined above. Likewise,  
               "alkylenyl," "alkenylenyl," and "alkynylenyl" are the divalent forms of the "alkyl,"

"alkenyl," and "alkynyl" groups defined above. For example, an arylalkylenyl group comprises an alkylene moiety to which an aryl group is attached.

The term "haloalkyl" is inclusive of alkyl groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of other groups that include the prefix "halo-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like. Similarly, the term "fluoroalkyl" is inclusive of groups that are substituted by one or more fluorine atoms, including perfluorinated groups (e.g., trifluoromethyl).

The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.

The term "heteroatom" refers to the atoms O, S, or N.

The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, pyrazinyl, 1-oxidopyridyl, pyridazinyl, triazinyl, tetrazinyl, oxadiazolyl, thiadiazolyl, and so on.

The term "heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups. Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, tetrahydropyranyl, quinuclidinyl, homopiperidinyl, homopiperazinyl, and the like.

The terms "arylene," "heteroarylene," and "heterocyclylene" are the divalent forms of the "aryl," "heteroaryl," and "heterocyclyl" groups defined above. Likewise, "arylenyl," "heteroarylenyl," and "heterocyclenyl" are the divalent forms of the "aryl," "heteroaryl," and "heterocyclyl" groups defined above. For example, an alkylarylenyl group comprises an arylene moiety to which an alkyl group is attached.

When a group or substituent is present more than once in any Formula described herein, each group or substituent is independently selected, whether specifically stated or not.



The invention is inclusive of the compounds described herein and salts thereof in any of their pharmaceutically acceptable forms, including isomers such as diastereomers and enantiomers, solvates, polymorphs, and the like. In particular, if a compound is optically active, the invention specifically includes each of the compound's enantiomers as well as racemic mixtures of the enantiomers.

#### Preparation of the Compounds

Compounds of the invention can be prepared according to Reaction Scheme I wherein R, R<sub>1a</sub>, R<sub>2a</sub>, and n are as defined above.

In step (1) of Reaction Scheme I, a 4-chloro-3-nitroquinoline of Formula III is reacted with *tert*-butyl carbazate or an alternate carbazate to provide a carbazate compound of Formula IV. The reaction can be carried out by adding *tert*-butyl carbazate to a solution of a compound of Formula III in a suitable solvent such as anhydrous dichloromethane in the presence of a base such as triethylamine. The reaction can be run at ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods. Many compounds of Formula III are known or can be prepared using known synthetic methods, see for example, U.S. Patent Nos. 4,689,338; 5,175,296; 5,367,076; and 5,389,640; and the documents cited therein. *Tertiary*-butyl carbazate is commercially available (for example, from Aldrich, Milwaukee, WI). Many alternate carbazate reagents (for example, benzyl carbazate) may be prepared using known synthetic methods.

In step (2) of Reaction Scheme I a carbazate compound of Formula IV is reduced to provide a compound of Formula V. The reduction can be carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon. For some compounds of Formula IV, for example, compounds in which R is halogen, a platinum catalyst is preferred. The reaction can be conveniently carried out on a Parr apparatus in a suitable solvent such as toluene and/or isopropanol. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

Other reduction processes may be used for the reduction in step (2). For example, an aqueous solution of sodium dithionite can be added to a solution or suspension of the

compound of Formula IV in a suitable solvent such as ethanol or isopropanol. The reaction can be carried out at an elevated temperature, for example at reflux, or at ambient temperature.

In step (3) of Reaction Scheme I a compound of Formula V is (i) reacted with an acyl halide of Formula  $R_{2a}C(O)Cl$  or  $R_{2a}C(O)Br$  and then (ii) cyclized to provide a 1*H*-imidazo compound of Formula VI. In part (i) the acyl halide is added to a solution of a compound of Formula V in a suitable solvent such as anhydrous dichloromethane in the presence of a base such as triethylamine. The reaction can be run at a reduced temperature, for example, 0° C, or at ambient temperature. In part (ii) the product of part (i) is heated in an alcoholic solvent in the presence of a base. For example, the product of part (i) is refluxed in ethanol in the presence of excess triethylamine or is heated with methanolic ammonia.

Alternatively, step (3) can be carried out by reacting a compound of Formula V with a carboxylic acid or an equivalent thereof. Suitable equivalents to carboxylic acid include orthoesters and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired  $R_{2a}$  substituent in a compound of Formula VI. For example, triethyl orthoformate will provide a compound where  $R_{2a}$  is hydrogen, and triethyl orthovalerate will provide a compound where  $R_{2a}$  is butyl. The reaction can be run in the absence of solvent or in an inert solvent such as anhydrous toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction. Optionally a catalyst such as pyridine hydrochloride can be included. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (4) of Reaction Scheme I, the *tert*-butoxycarbonyl or alternate oxycarbonyl group is removed from a 1*H*-imidazo compound of Formula VI by hydrolysis under acidic conditions to provide a 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula VIIa or a salt (for example, hydrochloride salt) thereof. For example, a compound of Formula VI is dissolved in 1.5M HCl in ethanol and heated to reflux. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (5a) of Reaction Scheme I, a 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula VIIa or a salt thereof is treated with a ketone, aldehyde, or corresponding ketal or acetal thereof, under acidic conditions to provide a compound of Formula VIII. For

example, a ketone is added to a solution of the hydrochloride salt of a compound of Formula VIIa in a suitable solvent such as isopropanol in the presence of an acid or acid resin, for example, DOWEX W50-X1 acid resin. The ketone, aldehyde, or corresponding ketal or acetal thereof, is selected with R<sub>i</sub> and R<sub>ii</sub> groups that will provide the desired R<sub>1a</sub> substituent in a 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula IXa. For example, acetone will provide a compound where R<sub>1a</sub> is isopropyl, and benzaldehyde will provide a compound where R<sub>1a</sub> is benzyl. The reaction is run with sufficient heating to drive off the water formed as a byproduct of the reaction. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

10 In step (6) of Reaction Scheme I, a compound of Formula VIII is reduced to provide a 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula IXa. The reaction can be carried out by adding sodium borohydride to a solution of a compound of Formula VIII in a suitable solvent, for example, methanol. The reaction can be run at ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

15 Alternatively, in step (5b) of Reaction Scheme I, a 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula VIIa can be treated with a ketone and a borohydride under acidic conditions to provide a 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula IXa. For example, the hydrochloride salt of a 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula VIIa, dissolved in a suitable solvent such as 1,2-dichloroethane, can be treated with a ketone and sodium triacetoxyborohydride at room temperature. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.


20 In step (7) of Reaction Scheme I, a 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula IXa is oxidized to provide an *N*-oxide of Formula Xa using a conventional oxidizing agent that is capable of forming *N*-oxides. The reaction is carried out by treating a solution of a compound of Formula IXa in a suitable solvent such as chloroform or dichloromethane with 3-chloroperoxybenzoic acid at ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

25 In step (8) of Reaction Scheme I, an *N*-oxide of Formula Xa is aminated to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula Ia, which is a subgenus of compounds of the Formulas I, I-1, I-2, and I-3. The reaction is carried out in two parts. In part (i) a compound of Formula Xa is reacted with an acylating agent. Suitable acylating

agents include alkyl- or arylsulfonyl chlorides (e.g., benzenesulfonyl chloride, methanesulfonyl chloride, and *p*-toluenesulfonyl chloride). In part (ii) the product of part (i) is reacted with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g. in the form of ammonium hydroxide) and ammonium salts (e.g.,  
5 ammonium carbonate, ammonium bicarbonate, ammonium phosphate). The reaction can be carried out by dissolving a compound of Formula Xa in a suitable solvent such as dichloromethane, adding ammonium hydroxide to the solution, and then adding *p*-toluenesulfonyl chloride. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

10 Alternatively, the oxidation of step (7) and the amination of step (8) can be carried out sequentially without isolating the product of the oxidation to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula Ia. In step (7), after the 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula IXa is consumed by reaction with  
15 3-chloroperoxybenzoic acid as described in step (7), the aminating and acylating agents are added to the reaction mixture as in step (8). The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

## Reaction Scheme I



5            Compounds of the invention can be prepared according to Reaction Scheme II wherein R, R<sub>1</sub>, R<sub>2a</sub> and n are as defined above.

10            In step (1) of Reaction Scheme II, a 1*H*-imidazo compound of Formula VI is oxidized to provide an *N*-oxide of Formula XI using the method of step (7) in Reaction Scheme I. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

              In step (2) of Reaction Scheme II, an *N*-oxide of Formula XI is aminated using the method of step (8) in Reaction Scheme I to provide a 4-amino compound of the Formula XIIa. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.


In step (3) of Reaction Scheme II, the *tert*-butoxycarbonyl or alternate oxycarbonyl group is removed from a 4-amino compound of the Formula XIIa using the method of step (4) in Reaction Scheme I to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula XIIIa or a salt (for example, hydrochloride salt) thereof. The product or a  
5 pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (4a) of Reaction Scheme II, a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula XIIIa is treated with a ketone, aldehyde, or corresponding ketal or acetal thereof, using the method of step (5a) in Reaction Scheme I to provide a compound of Formula XIVa. The ketone, aldehyde, or corresponding ketal or acetal thereof, is selected with R<sub>i</sub>  
10 and R<sub>ii</sub> groups that will provide the desired R<sub>1</sub> substituent in a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine compound of Formula Ib. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (5) of Reaction Scheme II, a compound of Formula XIVa is reduced to provide a 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula Ib using the method  
15 of step (6) in Reaction Scheme I. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

Alternatively, in step (4b) of Reaction Scheme II, a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula XIIIa can be treated with a ketone and a borohydride using the method of step (5b) of Reaction Scheme I to provide a 1*H*-imidazo[4,5-*c*]quinolin-1-  
20 amine compound of Formula Ib, which is a subgenus of compounds of the Formulas I, I-1, I-2, and I-3. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

## Reaction Scheme II




Compounds of the invention can be prepared according to Reaction Scheme III wherein R,  $R_1'$ ,  $R_{1a}$ ,  $R_{2a}$ , and n are as defined above.

5 In step (1) of Reaction Scheme III, a 4-chloro-3-nitroquinoline of Formula III is reacted with a hydrazino compound of Formula XVa to provide a compound of Formula XVI. The reaction can be carried out by adding the hydrazino compound of Formula XVa to a solution of a compound of Formula III in a suitable solvent such as anhydrous dichloromethane in the presence of a base such as triethylamine. The reaction can be run  
10 at ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods. Many hydrazino compounds of Formula XVa are commercially available; others can be readily prepared using known synthetic methods.

In step (2) of Reaction Scheme III, a compound of Formula XVI is reduced to provide a compound of Formula XVII using the methods of step (2) in Reaction Scheme I.  
15 The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (3) of Reaction Scheme III, a compound of formula XVII is cyclized using the methods of step (3) in Reaction Scheme I to provide a 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula IXb. The product of step (i) (described in step (3) of Reaction Scheme I) can be isolated to provide a compound of the following formula:



5

In part (ii) the product of part (i) can be refluxed in suitable solvent such as toluene in the presence of pyridine hydrochloride. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (4) of Reaction Scheme III, a 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula IXb is oxidized to provide an *N*-oxide of Formula X using the method of step (7) in Reaction Scheme I. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.


In step (5) of Reaction Scheme III, an *N*-oxide of Formula X is aminated using the method of step (8) in Reaction Scheme I to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula Ic, which is a subgenus of compounds of the Formulas I, I-1, I-2, and I-3. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Alternatively, the oxidation of step (4) and the amination of step (5) can be carried out sequentially without isolating the product of the oxidation to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula Ic. In step (4), after the 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula IXb is consumed by reaction with 3-chloroperoxybenzoic acid as described in step (4), the aminating and acylating agents are added to the reaction mixture as in step (5). The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

25



## Reaction Scheme III



5           Compounds of the invention can be prepared according to Reaction Scheme IV wherein R, R<sub>1</sub>, R<sub>2</sub> and n are as defined above.

10           In step (1) of Reaction Scheme IV, a 2,4-dichloro-3-nitroquinoline of Formula XVIII is reacted with *tert*-butyl carbazate or an alternate carbazate to provide a carbazate compound of Formula XIX. The reaction can be carried out by adding *tert*-butyl carbazate or an alternate carbazate to a solution of a 2,4-dichloro-3-nitroquinoline of Formula XVIII in a suitable solvent such as anhydrous dichloromethane in the presence of a base such as triethylamine. The reaction can be run at ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods. Many quinolines of Formula XVIII are known or can be prepared using known synthetic

15           methods (see for example, Andre et al., U.S. Patent No. 4,988,815 and references cited therein).

20           In step (2) of Reaction Scheme IV, a carbazate compound of Formula XIX is reduced to provide a 2-chloroquinolin-3-amine of Formula XX using the method of step (2) in Reaction Scheme I. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

          In step (3) of Reaction Scheme IV, a 2-chloroquinolin-3-amine of Formula XX is reacted with an acyl halide of formula R<sub>2</sub>C(O)Cl or R<sub>2</sub>C(O)Br, or a carboxylic acid or

equivalent thereof, using the methods of step (3) in Reaction Scheme I to provide a 4-chloro-1*H*-imidazo[4,5-*c*]quinoline of Formula XXI. The carboxylic acid or equivalent is selected such that it provides the desired R<sub>2</sub> substituent in compounds of Formula XXI. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (4) of Reaction Scheme IV, the *tert*-butoxycarbonyl or alternate oxycarbonyl group is removed from a 4-chloro-1*H*-imidazo[4,5-*c*]quinoline of Formula XXI using the method of step (4) of Reaction Scheme I to provide a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula XXII or a salt thereof. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (5a) of Reaction Scheme IV, a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula XXII or a salt thereof is treated with a ketone, aldehyde, or corresponding ketal or acetal using the method of step (5a) of Reaction Scheme I to provide a compound of Formula XXIII. The ketone, aldehyde, or corresponding ketal or acetal thereof, is selected with R<sub>i</sub> and R<sub>ii</sub> groups that will provide the desired R<sub>1</sub> substituent in a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula XXIVa. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.


In step (6) of Reaction Scheme IV, a compound of Formula XXIII is reduced using the method of step (6) in Reaction Scheme I to provide a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula XXIVa. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

Alternatively, in step (5b) of Reaction Scheme IV, a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula XXII can be treated with a ketone and a borohydride using the method of step (5b) in Reaction Scheme I to provide a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula XXIVa. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (7) of Reaction Scheme IV, a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula XXIVa is aminated to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula Id, which is a subgenus of compounds of the Formulas I, I-1, I-2, and I-3. The reaction is carried out by heating (e.g., 125-175°C) a compound of Formula XXIVa under pressure in a sealed reactor in the presence of a solution of ammonia in an alkanol. The

product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

## Reaction Scheme IV



5

Compounds of the invention can be prepared according to Reaction Scheme V wherein R, R<sub>1</sub>, R<sub>2</sub> and n are as defined above.

In step (1) of Reaction Scheme V, a 4-chloro-1H-imidazo[4,5-c]quinoline of Formula XXI is aminated, using the method of step (7) in Reaction Scheme IV, to provide a 4-amino compound of the Formula XII. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (2) of Reaction Scheme V, the *tert*-butoxycarbonyl or alternate oxycarbonyl group is removed from a 4-amino compound of the Formula XII using the method of step (4) of Reaction Scheme I to provide a 1H-imidazo[4,5-c]quinoline-1,4-diamine of

15

Formula XIII or a salt thereof. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.


In step (3a) of Reaction Scheme V, a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula XIII or a salt thereof is treated with a ketone, aldehyde, or corresponding ketal or acetal using the method of step (5a) of Reaction Scheme I to provide a compound of  
5 Formula XIV. The ketone, aldehyde, or corresponding ketal or acetal thereof, is selected with R<sub>i</sub> and R<sub>ii</sub> groups that will provide the desired R<sub>1</sub> substituent in a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine compound of Formula Id. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

10 In step (4) of Reaction Scheme V, a compound of Formula XIV is reduced using the method of step (6) in Reaction Scheme I to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine compound of Formula Id, which is a subgenus of compounds of the Formulas I, I-1, I-2, and I-3. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

15 Alternatively, in step (3b) of Reaction Scheme V, a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula XIII or a salt thereof can be treated with a ketone and a borohydride using the method of step (5b) in Reaction Scheme I to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine compound of Formula Id. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

20

## Reaction Scheme V



5 Compounds of the invention can also be prepared according to Reaction Scheme VI wherein R, R<sub>1</sub>' , R<sub>1</sub>, R<sub>2</sub> and n are as defined above.


In step (1) of Reaction Scheme VI, a 2,4-dichloro-3-nitroquinoline of Formula XVIII is reacted with a hydrazino compound of Formula XV, using the method of step (1) in Reaction Scheme III, to provide a compound of Formula XXV. The product or a  
10 pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (2) of Reaction Scheme VI, a compound of Formula XXV is reduced using the method of step (2) in Reaction Scheme I to provide a compound of Formula XXVI. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

15 In step (3) of Reaction Scheme VI, a compound of Formula XXVI is reacted with an acyl halide of formula R<sub>2</sub>C(O)Cl or R<sub>2</sub>C(O)Br, or a carboxylic acid or equivalent thereof using the methods of step (3) in Reaction Scheme I to provide a 4-chloro-1H-imidazo[4,5-c]quinolin-1-amine compound of Formula XXIV. The carboxylic acid or  
20 equivalent is selected such that it provides the desired R<sub>2</sub> substituent in a compound of Formula XXIV. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

In step (4) of Reaction Scheme VI, a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula XXIV is aminated using the method of step (7) in Reaction Scheme IV to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula Ie, which is a subgenus of compounds of the Formulas I, I-1, I-2, and I-3. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

5



10 Compounds of the invention can be prepared according to Reaction Scheme VII wherein R, R<sub>1</sub>', R<sub>2a</sub>, R<sub>4</sub>, n, and Y are as defined above, and X<sub>a</sub> is C<sub>1-20</sub> alkylene.

In step (1) of Reaction Scheme VII, a 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula VIIa or a salt thereof is treated with a ketal or acetal, containing a protected amino group, using the method of step (5a) of Reaction Scheme I to provide a compound of Formula XXVII. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

The amino ketal or acetal is selected with R<sub>1</sub>' and X groups that will provide the desired R<sub>1</sub>' and X groups in a 1*H*-imidazo[4,5-*c*]quinolin-1,4-diamine of Formula XXX, XXXI, or XXXII, which are subgenera of compounds of the Formulas I, I-1, I-2, and I-3. For example, *tert*-butyl (3,3-diethoxypropyl)carbamate will provide a compound where R<sub>1</sub>' is hydrogen and X is ethylene. The amino group of an amino ketal or acetal can be

20

protected with a *tert*-butoxycarbonyl or an alternate oxycarbonyl group. For example, 1-amino-3,3-diethoxypropane can be reacted with di-*tert*-butyl dicarbonate in a suitable solvent such as tetrahydrofuran (THF) in the presence of triethylamine to provide *tert*-butyl (3,3-diethoxypropyl)carbamate.

5 In step (2) of Reaction Scheme VII, a compound of Formula XXVII is reduced using the method of step (6) in Reaction Scheme I to provide a compound of Formula XXVIII, which is a subgenus of compounds of the Formula IX. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

10 In step (3) of Reaction Scheme VII, a compound of Formula XXVIII is oxidized to provide an *N*-oxide of Formula XXIX using the method of step (7) in Reaction Scheme I. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.

15 In step (4) of Reaction Scheme VII, an *N*-oxide of Formula XXIX is aminated using the method of step (8) in Reaction Scheme I to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula XXX, which is a subgenus of compounds of the Formulas I, I-1, I-2, and I-3. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

20 In step (5) of Reaction Scheme VII, a the *tert*-butoxycarbonyl or alternate oxycarbonyl group is removed from a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula XXX using the method of step (4) of Reaction Scheme I to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula XXXI, which is a subgenus of compounds of the Formulas I, I-1, I-2, and I-3. The product or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.


25 In step (6) of Reaction Scheme VII, a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula XXXI is converted to a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula XXXII using conventional methods. For example, a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula XXXI can react with an acid chloride of Formula  $R_4C(O)Cl$  to provide a compound of Formula XXXII in which Y is  $-C(O)-$ . In addition, a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula XXXI can react with sulfonyl chloride of Formula  $R_4S(O)_2Cl$  or a sulfonic anhydride of Formula  $(R_4S(O)_2)_2O$  to provide a compound of Formula XXXII in which Y is  $-S(O)_2-$ . Numerous acid chlorides of Formula  $R_4C(O)Cl$ , sulfonyl chlorides of Formula  $R_4S(O)_2Cl$ , and sulfonic anhydrides of

Formula  $(R_4S(O)_2)_2O$  are commercially available; others can be readily prepared using known synthetic methods. The reaction can be conveniently carried out by adding the acid chloride of Formula  $R_4C(O)Cl$ , sulfonyl chloride of Formula  $R_4S(O)_2Cl$ , or sulfonic anhydride of Formula  $(R_4S(O)_2)_2O$  to a cooled solution of a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula XXXI and a base such as triethylamine in a suitable solvent such as chloroform, dichloromethane, or acetonitrile. The reaction can be carried out at ambient temperature or at a sub-ambient temperature such as 0 °C. The product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Ureas of Formula XXXII, where Y is  $-C(R_7)-N(R_9)-$ , in which  $R_7$  is =O, and  $R_9$  is as defined above, can be prepared by reacting a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula XXXI with isocyanates of Formula  $R_4N=C=O$ . Numerous isocyanates of Formula  $R_4N=C=O$  are commercially available; others can be readily prepared using known synthetic methods. The reaction can be conveniently carried out by adding the isocyanate of Formula  $R_4N=C=O$  to a cooled solution of a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of the Formula XXXI in a suitable solvent such as dichloromethane or chloroform. The reaction can be carried out at ambient temperature or at a sub-ambient temperature such as 0 °C. Alternatively, a compound of Formula XXXI can be treated with a thioisocyanate of Formula  $R_4N=C=S$ , or a carbamoyl chloride of Formula  $R_4N(R_9)-C(O)Cl$  to provide a compound of Formula XXXII, where Y is  $-C(S)-N(R_9)-$ , in which  $R_9$ , is as defined above. The product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.




## Reaction Scheme VII



Compounds of the invention can be prepared according to Reaction Scheme VIII  
 5 where  $n$  is as defined above; each  $R_C$  is independently selected from the group consisting  
 of hydroxy, alkyl, and alkoxy; and  $R_{1b}$  and  $R_{2b}$  are a subset of  $R_1$  and  $R_2$ , respectively, as  
 defined above, which do not include those groups that one skilled in the art would  
 recognize as being susceptible to reduction under the acidic hydrogenation conditions in  
 step (1). These susceptible groups include, for example, alkenyl, alkynyl, and aryl groups,  
 10 and groups bearing nitro substituents.

In step (1) of Reaction Scheme VIII, a 1*H*-imidazo[4,5-*c*]quinolin-4-amine of Formula If is reduced to provide a 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine of Formula Ila, which is a subgenus of compounds of the Formulas II and II-1. The reaction can be conveniently carried out by suspending or dissolving a compound of Formula If in trifluoroacetic acid, adding platinum(IV) oxide, and hydrogenating under an atmosphere of hydrogen. The reaction can be carried out in a Parr apparatus. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Reaction Scheme VIII



10

Compounds of the invention may be prepared according to Reaction Scheme IX where R<sub>A</sub>, R<sub>1</sub>, R<sub>1'</sub>, R<sub>2</sub>, and n is as defined above; and each R<sub>a</sub> is independently alkyl. Steps (1) through (4) may be carried out as described in U.S. Patent No. 5,352,784 and documents cited therein. In step (1) the amino group of a compound of Formula XXXIII may be acylated to provide a compound of Formula XXXIV. The reaction may be conveniently carried out by reacting a compound of Formula XXXIII with an alkyl malonyl chloride in the presence of a base such as triethylamine in a suitable solvent such as methylene chloride. The product or a pharmaceutically acceptable salt thereof may be isolated using conventional methods. Certain compounds of Formula XXXIII are commercially available and others can be prepared as described in U.S. Patent No. 5,352,784 and documents cited therein. Alkyl malonyl chlorides are known, some of which are commercially available, and others can be made by known methods.

15

20

In step (2) of Reaction Scheme IX, a compound of Formula XXXIV may be cyclized to provide a compound of Formula XXXV. The reaction may be conveniently carried out by adding a solution of a compound of Formula XXXIV in a suitable solvent such as THF to a suspension of sodium hydride (or other base capable of removing a malonyl methylene proton) in a suitable solvent such as THF. The reaction may be run at

25

an elevated temperature, for example the reflux temperature. The product or a pharmaceutically acceptable salt thereof may be isolated using conventional methods.

In step (3) of Reaction Scheme IX, a compound of Formula XXXV may be hydrolyzed and decarboxylated to provide a compound of Formula XXXVI. The reaction may be carried out by conventional methods, for example, by combining a compound of Formula XXXV with an acid, such as hydrochloric acid, with heating. The product may be isolated using conventional methods.

In step (4) of Reaction Scheme IX, a compound of Formula XXXVI may be nitrated to provide a compound of Formula XXXVII. The reaction may be carried out under conventional nitration conditions, such as by heating a compound of Formula XXXVI in the presence of nitric acid, preferably in a solvent such as acetic acid. The product or a pharmaceutically acceptable salt thereof may be isolated using conventional methods.

In step (5) of Reaction Scheme IX, a compound of Formula XXXVII may be chlorinated to provide a 2,4-dichloro-3-nitro-5,6,7,8-tetrahydroquinoline of Formula XXXVIII. The reaction may be carried out by combining a compound of Formula XXXVII with a conventional chlorinating agent (e.g., phosphorus oxychloride, thionyl chloride, phosgene, oxalyl chloride, or phosphorus pentachloride), optionally in solvent such as *N,N*-dimethylformamide (DMF) or methylene chloride, with heating (e.g., at the reflux temperature). The product or a pharmaceutically acceptable salt thereof may be isolated from the reaction mixture using conventional methods.

In step (6) of Reaction Scheme IX, a 2,4-dichloro-3-nitro-5,6,7,8-tetrahydroquinoline of Formula XXXVIII may be reacted with a hydrazino compound of Formula XV ( $H_2N-N(R_1')(R_1)$ ), using the method of step (1) in Reaction Scheme III, to provide a compound of Formula XXXIX. The product or a pharmaceutically acceptable salt thereof may be isolated by conventional methods.


In step (7) of Reaction Scheme IX, a compound of Formula XXXIX may be reduced using the method of step (2) in Reaction Scheme I to provide a compound of Formula XL. The product or a pharmaceutically acceptable salt thereof may be isolated by conventional methods.

In step (8) of Reaction Scheme IX, a compound of Formula XL may be reacted with an acyl halide of formula  $R_2C(O)Cl$  or  $R_2C(O)Br$ , or a carboxylic acid or equivalent

thereof using the methods of step (3) in Reaction Scheme I to provide a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula XLI. The carboxylic acid or equivalent may be selected such that it provides the desired R<sub>2</sub> substituent in a compound of Formula II-1. The product or a pharmaceutically acceptable salt thereof may be  
5 isolated by conventional methods.

In step (9) of Reaction Scheme IX, a 4-chloro-1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula XLI may be aminated using the method of step (7) in Reaction Scheme IV to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula II-1. The product or a pharmaceutically acceptable salt thereof may be isolated by conventional  
10 methods.

Reaction Scheme IX



5 For some embodiments, compounds of the invention are prepared according to Reaction Scheme X, wherein R, R<sub>1a</sub>, R<sub>2a</sub>, and I are as defined above; Hal is chloro, bromo, or iodo; R<sub>3a</sub> is -Z'-R<sub>4'</sub>, -Z'-X'-R<sub>4'</sub>, -Z'-X'-Y'-R<sub>4'</sub>, or -Z'-X'-R<sub>5'</sub>; wherein R<sub>4'</sub>, Y', X', and R<sub>5'</sub> are as defined above; and Z' is a bond.

10 In step (1) of Reaction Scheme X, a 4-chloro-3-nitroquinoline of Formula XLIV is converted to a carbamate of Formula XLV according to the method described in step (1) of

Reaction Scheme I. Compounds of Formula XLIV can be readily prepared using known synthetic routes; see for example, U.S. Patent Nos. 4,689,338 (Gerster), 5,367,076 (Gerster), 6,331,539 (Crooks et al.), 6,451,810 (Coleman et al.), 6,541,485 (Crooks et al.) and the documents cited therein.

5 In steps (2) and (3) of Reaction Scheme X, a nitro-substituted quinoline of Formula XLV is first reduced to an amino-substituted quinoline of Formula XLVI, which is then cyclized to a 1*H*-imidazoquinoline of Formula XLVII. Steps (2) and (3) of Reaction Scheme X can be carried out as described for steps (2) and (3) of Reaction Scheme I.

10 In step (4) of Reaction Scheme X, the *tert*-butoxycarbonyl group of a 1*H*-imidazoquinoline of Formula XLVII is hydrolyzed under acidic conditions to provide a 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula VIIb or a pharmaceutically acceptable salt thereof. The reaction is conveniently carried out as described in step (4) of Reaction Scheme I.

15 The 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula VIIb is then converted to a 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula IXc using either a two-step procedure as shown in steps (5a) and (6) of Reaction Scheme X or a one-step procedure as shown in step (5b). The two-step procedure, in which a compound of Formula VIIIb is isolated, can be carried out as described in steps (5a) and (6) of Reaction Scheme I. In step (5a), the ketone, aldehyde, or corresponding ketal or acetal thereof, is selected with R<sub>i</sub> and R<sub>ii</sub> groups that will provide the desired R<sub>1a</sub> substituent in a 1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula IXc. Step (5b) of Reaction Scheme X can be carried out as described for step (5b) of Reaction Scheme I.

25 In steps (7) and (8) of Reaction Scheme X, a 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula IXc is first oxidized to an *N*-oxide of Formula Xb, which is then aminated to provide a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula Ig, which is a subgenus of the compounds of the Formulas I, I-1, I-2, and I-3. Steps (7) and (8) of Reaction Scheme X can be carried out according to the procedures described in steps (7) and (8) of Reaction Scheme I.

30 Step (9) of Reaction Scheme X can be carried out using known palladium-catalyzed coupling reactions such as Suzuki coupling, Stille coupling, Sonogashira coupling, and the Heck reaction. For example, a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula Ig undergoes Suzuki coupling with a boronic acid of Formula R<sub>3a</sub>-B(OH)<sub>2</sub>, an

anhydride thereof, or a boronic acid ester of Formula  $R_{3a}\text{-B(O-alkyl)}_2$  to provide an 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula I-1b, a subgenus of Formulas I and I-1, wherein  $R_{3a}$  is  $\text{-Z}'\text{-R}_4'$ ,

$\text{-Z}'\text{-X}'\text{-R}_4'$ ,  $\text{-Z}'\text{-X}'\text{-Y}'\text{-R}_4'$ , or  $\text{-Z}'\text{-X}'\text{-R}_5'$ ;  $\text{-Z}'$  is a bond;  $\text{-X}'$  is alkenylene, arylene, or

5 heteroarylene optionally terminated by arylene or heteroarylene; and  $R_4'$ ,  $Y'$ , and  $R_5'$  are as defined above. The coupling is carried out by combining a compound of Formula Ig with a boronic acid or an ester or anhydride thereof in the presence of palladium (II) acetate, triphenylphosphine, and a base such as sodium carbonate in a suitable solvent such as *n*-propanol. The reaction can be carried out at an elevated temperature (e.g., 80-100°C).  
10 Numerous boronic acids of Formula  $R_{3a}\text{-B(OH)}_2$ , anhydrides thereof, and boronic acid esters of Formula  $R_{3a}\text{-B(O-alkyl)}_2$  are commercially available; others can be readily prepared using known synthetic methods. See, for example, Li, W. et al, *J. Org. Chem.*, 67, 5394-5397 (2002). The product of Formula I-1b or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.


15 The Heck reaction can also be used in step (9) of Reaction Scheme X to provide compounds of Formula I-1b, wherein  $R_{3a}$  is  $\text{-Z}'\text{-X}'\text{-R}_4'$  or  $\text{-Z}'\text{-X}'\text{-Y}'\text{-R}_4'$ ;  $\text{-Z}'$  is a bond;  $\text{-X}'$  is alkenylene optionally terminated by arylene or heteroarylene; and  $R_4'$  and  $Y'$  are as defined above. The Heck reaction is carried out by coupling a 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula Ig with a vinyl-substituted arylene or heteroarylene  
20 compound. Several vinyl-substituted arylene or heteroarylene compounds, such as 2-vinylpyridine, 3-vinylpyridine, and 4-vinylpyridine, are commercially available; others can be prepared by known methods. The reaction is conveniently carried out by combining the 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula Ig and the vinyl-substituted compound in the presence of palladium (II) acetate, triphenylphosphine or tri-  
25 *ortho*-tolylphosphine, and a base such as triethylamine in a suitable solvent such as acetonitrile or toluene. The reaction can be carried out at an elevated temperature such as 100-120 °C under an inert atmosphere. The compound or pharmaceutically acceptable salt thereof can be isolated using conventional methods.

30 Compounds of Formula I-1b, wherein  $R_{3a}$  is  $\text{-Z}'\text{-X}'\text{-R}_4'$  or  $\text{-Z}'\text{-X}'\text{-Y}'\text{-R}_4'$ ,  $\text{-Z}'$  is a bond and  $\text{-X}'$  is alkenylene optionally terminated by arylene or heteroarylene, may be reduced to provide compounds wherein  $\text{-X}'$  is alkylene optionally terminated by arylene or heteroarylene. For example, compounds wherein  $R_{3a}$  is a 2-(pyridin-3-yl)ethyl group

may be prepared in this manner. The reduction can be carried out by hydrogenation using a conventional heterogeneous hydrogenation catalyst such as palladium on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as ethanol, methanol, or mixtures thereof. The compound or pharmaceutically acceptable salt thereof can be isolated using conventional methods.

5

Reaction Scheme X





For some embodiments, compounds of the invention can be prepared according to Reaction Scheme XI where R, R<sub>1a</sub>, R<sub>2a</sub>, and I are as defined above; Boc is *tert*-butoxycarbonyl; R<sub>3b</sub> is -Z'-R<sub>4</sub>', -Z'-X'-R<sub>4</sub>', -Z'-X'-Y'-R<sub>4</sub>', or -Z'-X'-R<sub>5</sub>'; X', Y', and R<sub>4</sub>' are as defined above; and Z' is -O-.

5 In step (1) of Reaction Scheme XI, a benzyloxyaniline of Formula XLVIII is treated with the condensation product generated from 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) and triethyl orthoformate to provide an imine of Formula XLIX. The reaction is conveniently carried out by adding a solution of a benzyloxyaniline of Formula XLVIII to a heated mixture of Meldrum's acid and triethyl orthoformate and heating the  
10 reaction at an elevated temperature such as 45 °C. The product can be isolated using conventional methods.

In step (2) of Reaction Scheme XI, an imine of Formula XLIX undergoes thermolysis and cyclization to provide a benzyloxyquinolin-4-ol of Formula L. The reaction is conveniently carried out in a heat transfer fluid such as DOWTHERM A heat  
15 transfer fluid at a temperature between 200 and 250 °C. The product can be isolated using conventional methods.

In step (3) of Reaction Scheme XI, a benzyloxyquinolin-4-ol of Formula L is nitrated under conventional nitration conditions to provide a benzyloxy-3-nitroquinolin-4-ol of Formula LI. The reaction is conveniently carried out by adding nitric acid to the  
20 benzyloxyquinolin-4-ol of Formula L in a suitable solvent such as propionic acid and heating the mixture at an elevated temperature such as 125 °C. The product can be isolated using conventional methods.

In step (4) of Reaction Scheme XI, a benzyloxy-3-nitroquinolin-4-ol of Formula LI is chlorinated using conventional chlorination chemistry to provide a benzyloxy-4-chloro-  
25 3-nitroquinoline of Formula LII. The reaction is conveniently carried out by treating the benzyloxy-3-nitroquinolin-4-ol of Formula LI with phosphorous oxychloride in a suitable solvent such as DMF. The reaction can be carried out at ambient temperature or at an elevated temperature such as 100 °C, and the product can be isolated using conventional methods.

30 In step (5) of Reaction Scheme XI, a benzyloxy-4-chloro-3-nitroquinoline of Formula LII is converted to a carbazate of Formula LIII. The reaction is conveniently carried out as described in step (1) of Reaction Scheme I.

In steps (6) and (7) of Reaction Scheme XI, a nitro-substituted quinoline of Formula LIII is first reduced to an amino-substituted quinoline of Formula LIV, which is then cyclized to a benzyloxy-1*H*-imidazo[4,5-*c*]quinoline of Formula LV. Steps (6) and (7) of Reaction Scheme XI can be carried out as described for steps (2) and (3) of Reaction Scheme I.

In step (8) of Reaction Scheme XI, the Boc group of a benzyloxy-1*H*-imidazo[4,5-*c*]quinoline of Formula LV is hydrolyzed under acidic conditions to provide a benzyloxy-1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula XLIIa or a pharmaceutically acceptable salt thereof. The reaction is conveniently carried out as described in step (4) of Reaction Scheme I.

The benzyloxy-1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula XLIIa is then converted to a benzyloxy-1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula XLIIIa using either a two-step procedure as shown in steps (9a) and (10) of Reaction Scheme XI or a one-step procedure as shown in step (9b). The two-step procedure, in which a compound of Formula LVI is isolated, can be carried out as described in steps (5a) and (6) of Reaction Scheme I. In step (9a), the ketone, aldehyde, or corresponding ketal or acetal thereof, is selected with R<sub>i</sub> and R<sub>ii</sub> groups that will provide the desired R<sub>1a</sub> substituent in a benzyloxy-1*H*-imidazo[4,5-*c*]quinolin-1-amine compound of Formula XLIIIa. Step (9b) of Reaction Scheme XI can be carried out as described for step (5b) of Reaction Scheme I.

In steps (11) and (12) of Reaction Scheme XI, a benzyloxy-1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula XLIIIa is first oxidized to an *N*-oxide of Formula LVII, which is then aminated to provide a benzyloxy-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula LVIII, which is a subgenus of the compounds of the Formulas I and I-1. Steps (11) and (12) of Reaction Scheme XI can be carried out according to the procedures described in steps (7) and (8) of Reaction Scheme I.

In step (13) of Reaction Scheme XI, the benzyl group of a benzyloxy-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula LVIII is cleaved to provide a hydroxy-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula I<sub>h</sub>. The cleavage is conveniently carried out on a Parr apparatus under hydrogenolysis conditions using a suitable heterogeneous catalyst such as palladium on carbon in a solvent such as ethanol. The product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.

In step (14) of Reaction Scheme XI a hydroxy-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula I*h* is converted to an ether-substituted 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula I-1*c* (a subgenus of compounds of Formulas I and I-1) using a Williamson-type ether synthesis. The reaction is effected by treating a compound of


5 Formula I*h* with an alkyl halide of Formula Halide-R<sub>4</sub>' , Halide-X'-Y'-R<sub>4</sub>' , Halide-X'-R<sub>4</sub>' , or Halide-X'-R<sub>5</sub>' in the presence of a base. The reaction is conveniently carried out by combining the alkyl halide with a compound of Formula I*h* in a solvent such as DMF in the presence of a suitable base such as cesium carbonate. The reaction can be carried out at ambient temperature or at an elevated temperature, for example 65 °C or 85 °C.

10 Alternatively, the reaction can be carried out by treating a solution of a compound of Formula I*h* in a solvent such as DMF with sodium hydride and then adding the alkyl halide. The product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Numerous reagents of Formulas Halide-R<sub>4</sub>' , Halide-X'-R<sub>4</sub>' , and Halide-X'-Y'-R<sub>4</sub>' are commercially available, for example, bromo-substituted ketones, esters, and heterocycles. Other reagents of Formulas Halide-R<sub>4</sub>' , Halide-X'-Y'-R<sub>4</sub>' , or Halide-X'-R<sub>5</sub>' can be prepared using conventional synthetic methods; for example, a bromo-substituted acid halide of Formula ClC(O)-X'-Br can be treated with a secondary amine in a suitable solvent such as dichloromethane to provide a variety of bromo-substituted amides of

20 Formula

Br-X'-C(O)-N(R<sub>11</sub>)-R<sub>4</sub>' or



The reaction can be run at a sub-ambient temperature such as -25 °C, and the product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.

25 Reagents of Formula I-X'-NH-C(O)-O-C(CH<sub>3</sub>)<sub>3</sub> can be prepared in two steps from amino alcohols of Formula HO-X'-NH<sub>2</sub>, many of which are commercially available or readily prepared by known synthetic methods. An amino alcohol of Formula HO-X'-NH<sub>2</sub> is first protected with a *tert*-butoxy carbonyl group by treating the amino alcohol with di-*tert*-butyl dicarbonate in the presence of a base such as aqueous sodium hydroxide in a


30 suitable solvent such as tetrahydrofuran. The resulting hydroxyalkylcarbamate of Formula

HO-X'-NH-C(O)-O-C(CH<sub>3</sub>)<sub>3</sub> is then treated with a solution of iodine, triphenylphosphine, and imidazole at ambient temperature in a suitable solvent such as dichloromethane. The product of Formula I-X'-NH-C(O)-O-C(CH<sub>3</sub>)<sub>3</sub> can be isolated using conventional methods.

Step (14) of Reaction Scheme XI can alternatively be carried out by treating a  
5 hydroxy-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula I*h* with an alcohol of  
Formula HO-X'-Y'-R<sub>4</sub>', HO-X'-R<sub>5</sub>', HO-X'-R<sub>4</sub>', or HO-R<sub>4</sub>' under Mitsunobu reaction  
conditions. Numerous alcohols of these formulas are commercially available, and others  
can be prepared using conventional synthetic methods. The reaction is conveniently  
carried out by adding triphenylphosphine and an alcohol of Formula HO-X'-Y'-R<sub>4</sub>',  
10 HO-X'-R<sub>5</sub>', HO-X'-R<sub>4</sub>', or HO-R<sub>4</sub>' to a solution of a compound of Formula I*h* in a suitable  
solvent such as tetrahydrofuran and then slowly adding diisopropyl azodicarboxylate or  
diethyl azodicarboxylate. The reaction can be carried out at ambient temperature or at a  
sub-ambient temperature, such as 0 °C. The product or pharmaceutically acceptable salt  
thereof can be isolated using conventional methods.


15 Compounds of Formula I-1*c*, wherein R<sub>3*b*</sub> is -O-X'-NH-C(O)-O-C(CH<sub>3</sub>)<sub>3</sub>, can be  
prepared by treating compounds of Formula I*h* with alcohols such as *tert*-butyl *N*-(4-  
hydroxybutyl)carbamate and *tert*-butyl *N*-(5-hydroxypentyl)carbamate under Mitsunobu  
conditions or with alkyl halides of Formula I-X'-NH-C(O)-O-C(CH<sub>3</sub>)<sub>3</sub> in a Williamson-  
type ether synthesis. These compounds of Formula I-1*c*, wherein R<sub>3*b*</sub> is  
20 -O-X'-NH-C(O)-O-C(CH<sub>3</sub>)<sub>3</sub>, are then readily converted to other compounds of Formula  
I-1*c* using conventional synthetic methods. For example, compounds in which R<sub>3*b*</sub> is  
-O-X'-NH-C(O)-O-C(CH<sub>3</sub>)<sub>3</sub> can be deprotected and treated according to the methods  
described in steps (5) and (6) of Reaction Scheme VII, Parts F and G of Example 14, and  
Examples 15 and 23 to provide compounds of Formula I-1*c* wherein R<sub>3*b*</sub> is -Z'-X'-Y'-R<sub>4</sub>';  
25 Z' is -O-; Y' is -NH-Q-; Q is -C(R<sub>7</sub>)-, -S(O)<sub>2</sub>-, or -C(R<sub>7</sub>)-N(R<sub>11</sub>)-; and X', R<sub>4</sub>', R<sub>7</sub>, and R<sub>11</sub>  
are as defined above. Compounds in which R<sub>3*b*</sub> is a 2-methanesulfonylaminoethoxy group  
or a 3-methanesulfonylaminoethoxy group are available using these methods.

## Reaction Scheme XI



For some embodiments, compounds of Formula I-1c can be prepared according to  
 5 Reaction Scheme XII, in which R, R<sub>1a</sub>, R<sub>2a</sub>, R<sub>3b</sub>, and l are as defined above. In step (1) of  
 Reaction Scheme XII, the benzyl group of a benzyloxy-1H-imidazo[4,5-c]quinolin-1-  
 amine of Formula XLIIa is cleaved to provide a hydroxy-1H-imidazo[4,5-c]quinolin-1-  
 amine of Formula IXd. In step (2) of Reaction Scheme XII a hydroxy-1H-imidazo[4,5-  
 c]quinolin-1-amine of Formula IXd is converted to an ether-substituted 1H-imidazo[4,5-  
 10 c]quinolin-1-amine of Formula LIX. In steps (3) and (4) of Reaction Scheme XII, an

ether-substituted 1*H*-imidazo[4,5-*c*]quinolin-1-amine of Formula LIX is first oxidized to an *N*-oxide of Formula LX, which is then aminated to provide an ether-substituted 1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine of Formula I-1c, which is a subgenus of the compounds of Formula I-1. Steps (1), (2), (3), and (4) of Reaction Scheme XII can be carried out as described in steps (13), (14), (11), and (12), respectively, of Reaction Scheme XI.



10

### Pharmaceutical Compositions and Biological Activity

Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound of the invention as described above in combination with a pharmaceutically acceptable carrier.

The term "a therapeutically effective amount" or "effective amount" means an amount of the compound sufficient to induce a therapeutic or prophylactic effect, such as cytokine induction, immunomodulation, antitumor activity, and/or antiviral activity. Although the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound, the nature of the carrier, and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about 100 ng/kg to about 50 mg/kg,

preferably about 10 µg/kg to about 5 mg/kg, of the compound to the subject. A variety of dosage forms may be used, such as tablets, lozenges, capsules, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.

5           The compounds of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds of the invention may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, antibodies, proteins, peptides, oligonucleotides, etc.

10           Compounds of the invention have been shown to modulate (e.g., induce) the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.

15           Cytokines whose production may be induced by the administration of compounds according to the invention generally include interferon- $\alpha$  (IFN- $\alpha$ ) and/or tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN- $\alpha$ , TNF- $\alpha$ , IL-1, IL-6, IL-10 and IL-12, and a variety of other cytokines. Among other effects, these and other cytokines  
20           can inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and neoplastic diseases. Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or composition of the invention to the animal. The animal to which the compound or composition is administered for induction of cytokine  
25           biosynthesis may have a disease as described *infra*, for example a viral disease or a neoplastic disease, and administration of the compound may provide therapeutic treatment. Alternatively, the compound may be administered to the animal prior to the animal acquiring the disease so that administration of the compound may provide a prophylactic treatment.

30           In addition to the ability to induce the production of cytokines, compounds of the invention may affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction.

Certain compounds may also activate macrophages, which in turn stimulate secretion of nitric oxide and the production of additional cytokines. Further, certain compounds may cause proliferation and differentiation of B-lymphocytes.

Compounds of the invention also have an effect on the acquired immune response. For example, the production of the T helper type 1 ( $T_H1$ ) cytokine IFN- $\gamma$  is induced indirectly and the production of the T helper type 2 ( $T_H2$ ) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of certain compounds.

Whether for prophylaxis or therapeutic treatment of a disease, and whether for effecting innate or acquired immunity, the compound or composition may be administered alone or in combination with one or more active components as in, for example, a vaccine adjuvant. When administered with other components, the compound and other component or components may be administered separately; together but independently such as in a solution; or together and associated with one another such as (a) covalently linked or (b) non-covalently associated, e.g., in a colloidal suspension.

Conditions for which IRMs identified herein may be used as treatments include, but are not limited to:

(a) viral diseases such as, for example, diseases resulting from infection by an adenovirus, a herpesvirus (e.g., HSV-I, HSV-II, CMV, or VZV), a poxvirus (e.g., an orthopoxvirus such as variola or vaccinia, or molluscum contagiosum), a picornavirus (e.g., rhinovirus or enterovirus), an orthomyxovirus (e.g., influenzavirus), a paramyxovirus (e.g., parainfluenzavirus, mumps virus, measles virus, and respiratory syncytial virus (RSV)), a coronavirus (e.g., SARS), a papovavirus (e.g., papillomaviruses, such as those that cause genital warts, common warts, or plantar warts), a hepadnavirus (e.g., hepatitis B virus), a flavivirus (e.g., hepatitis C virus or Dengue virus), or a retrovirus (e.g., a lentivirus such as HIV);

(b) bacterial diseases such as, for example, diseases resulting from infection by bacteria of, for example, the genus Escherichia, Enterobacter, Salmonella, Staphylococcus, Shigella, Listeria, Aerobacter, Helicobacter, Klebsiella, Proteus, Pseudomonas, Streptococcus, Chlamydia, Mycoplasma, Pneumococcus, Neisseria, Clostridium, Bacillus, Corynebacterium, Mycobacterium, Campylobacter, Vibrio, Serratia, Providencia, Chromobacterium, Brucella, Yersinia, Haemophilus, or Bordetella;



(c) other infectious diseases, such chlamydia, fungal diseases including but not limited to candidiasis, aspergillosis, histoplasmosis, cryptococcal meningitis, or parasitic diseases including but not limited to malaria, pneumocystis carinii pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and trypanosome infection; and

5 (d) neoplastic diseases, such as intraepithelial neoplasias, cervical dysplasia, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, renal cell carcinoma, Kaposi's sarcoma, melanoma, renal cell carcinoma, leukemias including but not limited to myelogenous leukemia, chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, B-cell lymphoma, and hairy cell leukemia, and  
10 other cancers; and

(e)  $T_H2$ -mediated, atopic, and autoimmune diseases, such as atopic dermatitis or eczema, eosinophilia, asthma, allergy, allergic rhinitis, systemic lupus erythematosus, essential thrombocythaemia, multiple sclerosis, Ommen's syndrome, discoid lupus, alopecia areata, inhibition of keloid formation and other types of scarring, and enhancing  
15 would healing, including chronic wounds.

IRMs identified herein also may be useful as a vaccine adjuvant for use in conjunction with any material that raises either humoral and/or cell mediated immune response, such as, for example, live viral, bacterial, or parasitic immunogens; inactivated viral, tumor-derived, protozoal, organism-derived, fungal, or bacterial immunogens,  
20 toxoids, toxins; self-antigens; polysaccharides; proteins; glycoproteins; peptides; cellular vaccines; DNA vaccines; recombinant proteins; glycoproteins; peptides; and the like, for use in connection with, for example, BCG, cholera, plague, typhoid, hepatitis A, hepatitis B, hepatitis C, influenza A, influenza B, parainfluenza, polio, rabies, measles, mumps, rubella, yellow fever, tetanus, diphtheria, hemophilus influenza b, tuberculosis,  
25 meningococcal and pneumococcal vaccines, adenovirus, HIV, chicken pox, cytomegalovirus, dengue, feline leukemia, fowl plague, HSV-1 and HSV-2, hog cholera, Japanese encephalitis, respiratory syncytial virus, rotavirus, papilloma virus, yellow fever, and Alzheimer's Disease.

IRMs may also be particularly helpful in individuals having compromised immune  
30 function. For example, IRM compounds may be used for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV patients.

Thus, one or more of the above diseases or types of diseases, for example, a viral disease or a neoplastic disease may be treated in an animal in need thereof (having the disease) by administering a therapeutically effective amount of a compound or salt of Formula I, I-1, I-2, I-3, II, or II-1 to the animal.


5 An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN- $\alpha$ , TNF- $\alpha$ , IL-1, IL-6, IL-10 and IL-12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is  
10 expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10  $\mu$ g/kg to about 5 mg/kg. The invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or composition of the invention to the animal. An amount effective to treat or inhibit a viral infection is an amount that will  
15 cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise amount that is effective for such treatment will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10  $\mu$ g/kg to about 5 mg/kg. An amount of a compound effective to treat  
20 a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10  $\mu$ g/kg to about 5 mg/kg.

25

#### EXAMPLES

Objects and advantages of this invention are further illustrated by the following examples, but the particular materials and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this invention.

## Example 1

2-Butyl-*N*<sup>1</sup>-isopropyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine

## 5 Part A

A solution of 4-chloro-3-nitroquinoline (5.00 g, 24.0 mmol) in 120 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> was treated with triethylamine (6.7 mL, 48.2 mmol) and *tert*-butyl carbazate (3.20 g, 24.2 mmol). After stirring under nitrogen for 2.5 hour (h), an additional portion of *tert*-butyl carbazate (3.2 g, 24.2 mmol) was added. After stirring overnight, the deep red solution was washed with H<sub>2</sub>O (2X) and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give a red foam. The material was passed through a SiO<sub>2</sub> column eluting with 2.5% methanol/CH<sub>2</sub>Cl<sub>2</sub>. The resulting red powder was treated with 5:1 hexanes/CH<sub>2</sub>Cl<sub>2</sub> and filtered. The solid was washed several times with hexanes and was dried under vacuum to give *tert*-butyl *N*'-(3-nitroquinolin-4-yl)hydrazinecarboxylate (4.97 g) as an orange powder.

## Part B

A suspension of *tert*-butyl *N*'-(3-nitroquinolin-4-yl)hydrazinecarboxylate (2.50 g, 8.22 mmol) in 150 mL of isopropanol was treated with 1.0 g of 10% palladium on carbon and the mixture was shaken under an atmosphere of hydrogen (3.8 x 10<sup>5</sup> Pa) for 2 h. The reaction mixture was then filtered through a pad of CELITE filter agent and rinsed with isopropanol, and the filtrate was concentrated under reduced pressure to give *N*'-(3-aminoquinolin-4-yl)hydrazine *tert*-butyl carboxylate (2.18 g) as a yellow solid.

## 25 Part C

A solution of *N*'-(3-aminoquinolin-4-yl)hydrazine *tert*-butyl carboxylate (2.18 g, 7.96 mmol) in 80 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> was cooled to 0 °C and treated with triethylamine (1.12 mL, 8.00 mmol) and valeryl chloride (0.95 mL, 8.00 mmol) under an

atmosphere of nitrogen. After stirring for 3 h, the reaction mixture was concentrated under reduced pressure and the residue was treated with Et<sub>2</sub>O and filtered. The filtrate was concentrated and the resulting black tar was dissolved in 80 mL of ethanol and treated with 3 mL of triethylamine and the mixture was refluxed overnight. The reaction mixture was concentrated under reduced pressure. Chromatography (SiO<sub>2</sub>, 1-5% methanol (MeOH)/CHCl<sub>3</sub>) gave *tert*-butyl *N*-(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)carbamate (1.41 g) as a mauve foam.

#### Part D

*tert*-Butyl *N*-(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)carbamate (830 mg, 2.44 mmol) was dissolved in 20 mL of 1.5 M HCl in ethanol (EtOH) and the reaction mixture was heated to reflux for 1.5 h. The reaction mixture was cooled and concentrated under reduced pressure to give a brown solid. The material was dissolved in 50 mL of hot isopropanol and the solution was allowed to cool overnight. The resulting crystals were isolated by filtration. A second crop was obtained from the filtrate by crystallization from isopropanol/Et<sub>2</sub>O. The total yield of 2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-amine hydrochloride was 570 mg. mp > 250 °C. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>) δ 9.68 (s, 1H), 9.35 (d, J = 8.3 Hz, 1H), 8.47 (d, J = 8.0 Hz, 1H), 8.03 (t, J = 7.1 Hz, 1H), 7.98 (t, J = 7.1 Hz, 1H), 6.85 (s, 2H), 3.13 (t, J = 7.6 Hz, 2H), 1.89, (m, 2H), 1.49 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>) δ 163.5, 139.4, 136.1, 134.0, 131.8, 130.4, 128.9, 122.6, 120.2, 115.6, 28.2, 25.7, 22.1, 13.3; Anal. Calcd for C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>·HCl: C, 60.76; H, 6.19; N, 20.24; Cl, 12.81. Found: C, 60.78; H, 6.19; N, 20.21; Cl, 12.78.

#### Part E

A solution of 2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-amine hydrochloride (520 mg, 2.17 mmol) in 10 mL of isopropanol was treated with 2 mL of acetone and 200 mg of DOWEX W50-X1 acid resin. The reaction mixture was heated to 55 °C overnight. The reaction mixture was treated with an additional 10 mL of isopropanol and 5 mL of acetone and heated to 70 °C for 2 h. The reaction mixture was filtered and the filtrate was treated with 0.5 mL of triethylamine and concentrated under reduced pressure. Chromatography (SiO<sub>2</sub>, 3% MeOH/CHCl<sub>3</sub>) gave *N*-(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylideneamine (421 mg) as a brown oil.

## Part F

A solution of *N*-(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylideneamine (406 mg, 1.45 mmol) in 15 mL of MeOH was treated with NaBH<sub>4</sub> (500 mg, 13.2 mmol). After stirring for 2 days (d), the reaction was quenched with saturated NaHCO<sub>3</sub> solution and extracted into ethyl acetate (EtOAc). The organic portion was washed with H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (SiO<sub>2</sub>, EtOAc) gave *N*-(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylamine (372 mg) as a mauve solid.

## 10 Part G

A solution of *N*-(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylamine (334 mg, 1.18 mmol) in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> was treated with 3-chloroperoxybenzoic acid (MCPBA) (77% max., 334 mg, 1.45 mmol). After stirring for 3 h, the reaction was quenched with saturated NaHCO<sub>3</sub> solution and extracted into CH<sub>2</sub>Cl<sub>2</sub>. The organic portion was washed with saturated NaHCO<sub>3</sub> solution, H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give *N*-(2-butyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylamine (338 mg) as a light brown solid.


## Part H

20 A solution of *N*-(2-butyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylamine (332 mg, 1.11 mmol) in 15 mL of 1,2-dichloroethane was placed in a pressure vessel and heated to 70 °C. The rapidly stirred solution was then treated with 3 mL of concentrated NH<sub>4</sub>OH solution and *p*-toluenesulfonyl chloride (233 mg, 1.22 mmol), the reaction vessel was capped, and heating was continued for 2 h. The reaction mixture was then cooled to ambient temperature and treated with 50 mL of CH<sub>2</sub>Cl<sub>2</sub>. The reaction mixture was washed with H<sub>2</sub>O, 1% Na<sub>2</sub>CO<sub>3</sub> solution (3X), H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. Chromatography (SiO<sub>2</sub>, 5-10% MeOH/CHCl<sub>3</sub>) gave 320 mg of a light brown solid. Crystallization from CH<sub>2</sub>Cl<sub>2</sub>/hexanes gave 2-butyl-*N*<sup>1</sup>-isopropyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine (230 mg) as colorless crystals. mp 157.1-158.7 °C. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>) δ 8.40 (m, 1H), 7.80 (m, 1H), 7.50 (m, 1H), 7.31 (m, 1H), 5.41 (s, 2H), 4.95 (s, 1H), 3.68 (m, 1H), 2.96 (t, J = 7.6 Hz, 2H), 1.93-1.82 (m, 2H), 1.48 (m, 2H), 1.16 d, J = 6.4 Hz, 6H), 1.00 (t, J = 7.3 Hz, 3H); <sup>13</sup>C NMR (75

MHz, DMSO-d<sub>6</sub>) δ 155.1, 151.8, 144.7, 133.1, 127.3, 126.6, 124.7, 122.0, 120.4, 115.3, 52.1, 30.3, 26.8, 23.0, 20.8, 14.2; MS m/z 298 (M + H)<sup>+</sup>; Anal. Calcd for C<sub>17</sub>H<sub>23</sub>N<sub>5</sub>: C, 68.66; H, 7.80; N, 23.55. Found: C, 68.30; H, 7.68; N, 23.33.

5

## Example 2

*N*<sup>1</sup>-Benzyl-2-butyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine

## 10 Part A

A solution of 2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-amine hydrochloride (503 mg, 1.82 mmol) in 10 mL of isopropanol was treated with benzaldehyde (220 μL, 2.17 mmol) and 200 mg of DOWEX W50-X1 acid resin. The reaction mixture was heated to reflux overnight. The reaction mixture was filtered, and the filtrate was treated with 0.5 mL of triethylamine and concentrated under reduced pressure. The resulting oil was dissolved in 75 mL of CH<sub>2</sub>Cl<sub>2</sub> and washed with saturated NaHCO<sub>3</sub> solution, H<sub>2</sub>O and brine. The organic was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give *N*-benzylidene(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (575 mg) as a light yellow solid.

## 20 Part B

A solution of *N*-benzylidene(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (575 mg, 1.75 mmol) in 40 mL of MeOH was treated with NaBH<sub>4</sub> (250 mg, 6.58 mmol). After stirring for 4 h, the reaction was quenched with saturated NaHCO<sub>3</sub> solution and extracted into CHCl<sub>3</sub>. The organic portion was washed with H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (SiO<sub>2</sub>, 50-67% EtOAc/hexanes) gave *N*-benzyl(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (427 mg) as a yellow solid.

25

## Part C


A solution of *N*-benzyl(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (427 mg, 1.29 mmol) in 20 mL of CH<sub>2</sub>Cl<sub>2</sub> was treated with MCPBA (77% max., 325 mg, 1.41 mmol). After stirring for 3 h, the reaction was quenched with saturated NaHCO<sub>3</sub> solution and extracted into CH<sub>2</sub>Cl<sub>2</sub>. The organic portion was washed with saturated NaHCO<sub>3</sub> solution, H<sub>2</sub>O and brine. The organic was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give *N*-benzyl(2-butyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (393 mg) as a light brown foam.

## 10 Part D

A solution of *N*-benzyl(2-butyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (393 mg, 1.14 mmol) in 20 mL of 1,2-dichloroethane was placed in a pressure vessel and heated to 70 °C. The rapidly stirred solution was then treated with 5 mL of concentrated NH<sub>4</sub>OH solution and *p*-toluenesulfonyl chloride (239 mg, 1.25 mmol), the reaction vessel was capped, and heating was continued for 2 h. The reaction mixture was then cooled to ambient temperature and treated with 50 mL of CH<sub>2</sub>Cl<sub>2</sub>. The reaction mixture was washed with H<sub>2</sub>O, 1% Na<sub>2</sub>CO<sub>3</sub> solution (3X), H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. Chromatography (SiO<sub>2</sub>, 5% MeOH/CHCl<sub>3</sub>) followed by crystallization from propyl acetate/hexanes gave *N*<sup>1</sup>-benzyl-2-butyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine (237 mg) as light-yellow crystals. mp 159.3-160.5 °C. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>) δ 8.31 (d, *J* = 8.2 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 1H), 7.54 (m, 1H), 7.42-7.31 (m, 6H), 5.44 (s, 2H), 5.26 (t, *J* = 5.6 Hz, 1H), 4.37 (d, *J* = 5.6 Hz, 2H), 2.71 (t, *J* = 8.4 Hz, 2H), 1.74 (m, 2H), 1.42 (m, 2H), 0.95 (t, *J* = 7.3 Hz, 3H); MS *m/z* 346 (M + H)<sup>+</sup>; Anal. Calcd for C<sub>21</sub>H<sub>23</sub>N<sub>5</sub>: C, 73.02; H, 6.71; N, 20.27. Found: C, 72.75; H, 6.55; N, 20.46.

25

## Example 3

*N*<sup>1</sup>-Isopropyl-2-methyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine

## Part A

A solution of *N*'-(3-aminoquinolin-4-yl)hydrazine *tert*-butyl carboxylate (11.67 g, 42.5 mmol) in 400 mL of anhydrous toluene was treated with trimethyl orthoacetate (5.96 mL, 46.8 mmol) and pyridine hydrochloride (100 mg) under an atmosphere of N<sub>2</sub> and heated to reflux. After stirring for 3 h, the reaction mixture was concentrated under reduced pressure to give a red solid. Chromatography (SiO<sub>2</sub>, 0-10% MeOH/EtOAc) gave *tert*-butyl *N*-(2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)carbamate (10.7 g) as a yellow foam.

10

## Part B

*tert*-Butyl *N*-(2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)carbamate (5.00 g, 16.8 mmol) was dissolved in 40 mL of 1.65 M HCl in EtOH, and the reaction mixture was heated to reflux for 2 h. The reaction mixture was cooled and concentrated under reduced pressure to give a brown solid. The brown solid was crystallized from ethanol/H<sub>2</sub>O to give 3.13 g of 2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-amine hydrochloride.

15

## Part C

A suspension of 2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-amine hydrochloride (1.79 g, 7.62 mmol) in 30 mL of 2,2-dimethoxypropane was treated with 90 mg of *p*-toluenesulfonic acid. The reaction mixture was heated to 100 °C overnight. The reaction mixture was then treated with 10 mL of H<sub>2</sub>O and 10 mL of MeOH, and heating was continued for 24 h. The reaction mixture was cooled and concentrated under reduced pressure. The resulting oil was dissolved in 50 mL of CHCl<sub>3</sub> and washed with 2% Na<sub>2</sub>CO<sub>3</sub> solution, H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give *N*-isopropylidene(2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (1.82 g) as a yellow solid.

20

25

## Part D

A solution of *N*-isopropylidene(2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (1.82 g, 7.64 mmol) dissolved in 40 mL of MeOH was treated with NaBH<sub>4</sub> (1.16 g, 30.6 mmol). After stirring for 18 h, the reaction was quenched with saturated NH<sub>4</sub>Cl solution

30



and partitioned between CH<sub>2</sub>Cl<sub>2</sub> and 2% Na<sub>2</sub>CO<sub>3</sub> solution. The organic portion was washed with 2% Na<sub>2</sub>CO<sub>3</sub> solution, H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The resulting organic portion was filtered and concentrated under reduced pressure to give *N*-isopropyl(2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (1.84 g) as a yellow foam.

5

## Part E

A solution of *N*-isopropyl(2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (1.84 g, 7.66 mmol) dissolved in 50 mL of 1,2-dichloroethane was treated with MCPBA (77% max., 2.36 g, 9.58 mmol). After stirring for 3 h, the reaction mixture was treated with 2% Na<sub>2</sub>CO<sub>3</sub> solution and extracted into CH<sub>2</sub>Cl<sub>2</sub>. The organic portion was washed with saturated 2% Na<sub>2</sub>CO<sub>3</sub> solution, H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give *N*-isopropyl(2-methyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (1.95 g) as a light orange solid.


15

## Part F

A solution of *N*-isopropyl(2-methyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (1.95 g, 7.61 mmol) in 75 mL of CH<sub>2</sub>Cl<sub>2</sub> was treated with 35 mL of concentrated NH<sub>4</sub>OH solution. To the rapidly stirred solution was added *p*-toluenesulfonyl chloride (1.52 g, 7.99 mmol). After stirring for 30 min, the reaction mixture was treated with CHCl<sub>3</sub> (25 mL) and H<sub>2</sub>O (35 mL). The layers were separated and the organic portion was washed with 2% Na<sub>2</sub>CO<sub>3</sub> solution (2X), H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give a light-yellow solid. Crystallization from propyl acetate gave *N*<sup>1</sup>-isopropyl-2-methyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine (747 mg) as off-white crystals. mp 227–229 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.19 (dd, J = 8.2, 1.1 Hz, 1 H), 7.79 (dd, J = 8.4, 0.7 Hz, 1 H), 7.53–7.45 (m, 1 H), 7.33–7.26 (m, 1 H), 5.42 (s, 2 H), 4.91 (d, J = 1.4 Hz, 1 H), 3.73–3.62 (m, 1 H), 2.64 (s, 3 H), 1.15 (d, J = 6.2 Hz, 6 H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 151.4, 151.3, 144.9, 133.3, 127.6, 127.3, 124.6, 122.4, 120.2, 115.4, 52.3, 20.9, 13.8; MS m/z 256 (M + H)<sup>+</sup>; Anal. Calcd for C<sub>14</sub>H<sub>17</sub>N<sub>5</sub>: C, 65.86; H, 6.71; N, 27.43; Found: C, 65.59; H, 6.56; N, 27.09.

30

## Example 4

*N*<sup>1</sup>-Benzyl-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine

## 5 Part A

A solution of *N*'-(3-aminoquinolin-4-yl)hydrazine *tert*-butyl carboxylate (12.15 g, 44.3 mmol) in 200 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> was cooled to 0 °C and treated with triethylamine (7.72 mL, 55.4 mmol) and 2-ethoxyacetyl chloride (5.70 g, 46.5 mmol) under an atmosphere of N<sub>2</sub>. After 3 h, an additional 1 mL of 2-ethoxyacetyl chloride was added. After stirring for 2 h, the reaction mixture was concentrated under reduced pressure to give a brown solid. This was dissolved in 150 mL of EtOH and treated with 18.5 mL of triethylamine, and the mixture was refluxed overnight. The reaction mixture was concentrated under reduced pressure to give a dark-red oil. The red oil was dissolved in 200 mL of CH<sub>2</sub>Cl<sub>2</sub> and washed with H<sub>2</sub>O (2 X 75 mL) and brine (75 mL). The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a red solid. The solid was treated with a minimum amount of hot Et<sub>2</sub>O and filtered to remove insoluble material. The filtrate was concentrated to give *tert*-butyl *N*-(2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)carbamate (14.3 g) as a tan solid.

## 20 Part B

*tert*-Butyl *N*-(2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)carbamate (14.3 g, 41.8 mmol) was dissolved in 150 mL of 2 M HCl in EtOH, and the reaction mixture was heated to reflux for 3 h. The reaction mixture was cooled and concentrated under reduced pressure to give a brown solid. The brown solid was dissolved in 100 mL of H<sub>2</sub>O and treated with 100 mL of concentrated NH<sub>4</sub>OH solution. The basic, aqueous solution was then extracted with CH<sub>2</sub>Cl<sub>2</sub> (4X). The combined organic layers were then washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solution was filtered and concentrated under reduced

pressure to give a brown foam. The foam was triturated with Et<sub>2</sub>O (150 mL) and filtered. The filtrate was concentrated to give 2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-amine (5.77 g) as a tan solid.

5 Part C

A solution of 2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-amine (1.50 g, 6.19 mmol) in 50 mL of isopropanol was treated with benzaldehyde (0.66 mL, 6.50 mmol) and 10 mg of *p*-toluenesulfonic acid. The reaction mixture was heated to 120 °C for 3 d. The reaction mixture was cooled, and a precipitate started to form. The reaction mixture was  
10 treated with Et<sub>2</sub>O and then filtered to give *N*-benzylidene-(2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (1.21 g) as a gray solid.

Part D

A solution of *N*-benzylidene-(2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (1.00 g, 3.03 mmol) in 50 mL of MeOH was treated with NaBH<sub>4</sub> (458 mg, 12.1 mmol). After stirring for 1.5 h, the reaction mixture was concentrated, then treated with saturated NaHCO<sub>3</sub> solution, and extracted into CHCl<sub>3</sub>. The organic portion was washed with H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The resulting solution was filtered and concentrated to give *N*-benzyl-(2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine  
15 (1.01 g) as a tan solid.

Part E

A solution of *N*-benzyl-(2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (1.01 g, 3.04 mmol) in 50 mL of CH<sub>2</sub>Cl<sub>2</sub> was treated with MCPBA (77% max., 1.02 g, 4.56 mmol). After stirring for 3 h, the reaction mixture was quenched with 2% Na<sub>2</sub>CO<sub>3</sub> solution and extracted into CH<sub>2</sub>Cl<sub>2</sub>. The organic portion was washed with H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give *N*-benzyl-(2-ethoxymethyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (0.99 g) as a light-yellow solid.  
25


30

## Part F

A solution of *N*-benzyl-(2-ethoxymethyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)amine (0.99 g, 2.84 mmol) in 50 mL of CH<sub>2</sub>Cl<sub>2</sub> was treated with 25 mL of concentrated NH<sub>4</sub>OH solution. To the rapidly stirred solution was added *p*-toluenesulfonyl chloride (569 mg, 2.98 mmol). After stirring for 30 min, the reaction was treated with CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and H<sub>2</sub>O (25 mL). The layers were separated and the organic portion was washed 2% Na<sub>2</sub>CO<sub>3</sub> solution, H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give a tan solid. Chromatography (SiO<sub>2</sub>, 2% MeOH/CHCl<sub>3</sub> containing 0.5% concentrated NH<sub>4</sub>OH) followed by crystallization from propyl acetate gave *N*<sup>1</sup>-benzyl-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine (148 mg) as white needles. mp 152–155 °C; <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>) δ 8.61 (dd, *J* = 8.2, 1.2 Hz, 1 H), 7.85–7.77 (m, 1 H), 7.59–7.52 (m, 1 H), 7.42–7.34 (m, 4 H), 7.33–7.24 (m, 2 H), 6.02 (t, *J* = 6.6 Hz, 1 H), 5.39 (s, 2 H), 4.43 (s, 2 H), 4.40 (d, *J* = 6.7 Hz, 2 H), 3.55 (q, *J* = 7.0 Hz, 2 H), 1.22 (t, *J* = 7.0 Hz, 3 H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 151.1, 147.9, 144.9, 135.7, 129.2, 129.1, 128.6, 127.8, 126.7, 122.4, 120.7, 66.7, 65.3, 56.7, 15.0; MS *m/z* 348 (*M* + *H*)<sup>+</sup>; Anal. Calcd for C<sub>20</sub>H<sub>21</sub>N<sub>5</sub>O·0.36H<sub>2</sub>O: C, 68.90; H, 6.11; N, 20.09; Found: C, 68.50; H, 6.07; N, 20.11.

## Example 5

2-Ethoxymethyl-*N*<sup>1</sup>-isopropyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine



## Part A

A solution of 2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-amine (2.50 g, 10.3 mmol) in 250 mL of 1,2-dichloroethane was treated with acetone (0.83 mL, 11.3 mmol), acetic acid (0.65 mL, 11.3 mmol) and sodium triacetoxyborohydride (2.39 g, 11.3 mL). After stirring overnight, additional acetone (5 mL), acetic acid (0.65 mL, 11.3 mmol) and sodium triacetoxyborohydride (2.39 g, 11.3 mL) were added. After 2 d, the reaction was

carefully quenched by addition of saturated NaHCO<sub>3</sub> solution. The layers were separated and the aqueous portion was extracted with additional CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to give a brown oil. Some isopropylidene intermediate was still present, so the material was dissolved in 50 mL of MeOH and treated with NaBH<sub>4</sub> (1.0 g). After 2 h, the reaction was quenched by the addition of H<sub>2</sub>O and the reaction mixture was concentrated under reduced pressure. The residue was partitioned between saturated NaHCO<sub>3</sub> solution and CH<sub>2</sub>Cl<sub>2</sub>. The layers were separated and the organic portion was washed with saturated NaHCO<sub>3</sub>, H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. Chromatography (SiO<sub>2</sub>, 4% MeOH/CHCl<sub>3</sub>) gave *N*-(2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylamine (0.98 g) as a brown oil.

#### Part B

A solution of *N*-(2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylamine (0.98 g, 3.45 mmol) in 35 mL of CH<sub>2</sub>Cl<sub>2</sub> was treated with MCPBA (77% max., 1.10 g, 4.48 mmol). After stirring for 3 h, the reaction was quenched with 2% Na<sub>2</sub>CO<sub>3</sub> solution and extracted into CH<sub>2</sub>Cl<sub>2</sub>. The organic portion was washed with H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give *N*-(2-ethoxymethyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylamine (0.93 g) as a light-orange solid.

#### Part C

A solution of *N*-(2-ethoxymethyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)isopropylamine (0.93 g, 3.10 mmol) in 25 mL of CH<sub>2</sub>Cl<sub>2</sub> was treated with 15 mL of concentrated NH<sub>4</sub>OH solution. To the rapidly stirred solution was added *p*-toluenesulfonyl chloride (620 mg, 3.25 mmol). After stirring for 30 min, the reaction was treated with CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and H<sub>2</sub>O (15 mL). The layers were separated and the organic portion was washed with 2% Na<sub>2</sub>CO<sub>3</sub> solution, H<sub>2</sub>O and brine. The organic portion was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give a tan solid. Chromatography (SiO<sub>2</sub>, 5% MeOH/CHCl<sub>3</sub>) gave 2-ethoxymethyl-*N*<sup>1</sup>-isopropyl-1*H*-imidazo[4,5-*c*]quinoline-1,4-diamine (368 mg) as a tan solid. mp 162–164 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.60 (dd,